<TRIAL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-HN001</PROTOCOL_NO>
    <TITLE>Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)</TITLE>
    <NCT_ID>NCT02135042</NCT_ID>
    <SHORT_TITLE>Phase2/3 study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker EBV DNA</SHORT_TITLE>
    <INVESTIGATOR_NAME>Rupali Nabar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx
Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis.

Patients must have detectable pretreatment plasma EBV DNA, determined by the central lab prior to Step 2 registration (see Section 10.2 for details of specimen submission).
For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs (listed on the EBV DNA Testing Specimen Transmittal form) within 28 days prior to Step 1 registration: that test result can be used for eligibility without the need for re-testing. To use this test result for eligibility, the central lab must enter the test result through the pathology portal, and the site must follow the instructions in Section 5.4.
Stage II-IVB disease (AJCC, 7th ed.) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:

History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or ENT, which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration;
Evaluation of tumor extent required within 28 days prior to registration:
MRI of the nasopharynx and neck; or CT of the nasopharynx and neck with &amp;#8804; 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement).
Note: If a treatment planning CT scan is used, it must be with &amp;#8804; 3 mm contiguous slices with contrast and be read by a radiologist.

Exclusion Criteria:

Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; however, at least 6-weeks recovery is necessary if the last regimen included nitrosourea or mitomycin
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
&amp;#8805; Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)
Severe, active co-morbidity, defined as follows:

Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy
Unstable angina and/or uncontrolled congestive heart failure within the past 6 months
Myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that Human Immunodeficiency Virus (HIV) testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception</DETAILED_ELIGIBILITY>
    <DESCRIPTION>There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-06T22:40:08</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Radiation Therapy Oncology Group</SPONSOR_NAME>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-14-89</PROTOCOL_NO>
    <TITLE>[BIOREPOSITORY] Hematologic Malignancies Biorepository for human research</TITLE>
    <NCT_ID />
    <SHORT_TITLE>BIOREPOSITORY PROTOCOL EXEMPT FROM NCI REPORTING</SHORT_TITLE>
    <INVESTIGATOR_NAME>Angela G Fleischman</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you have or are being evaluated for a blood disorder

Exclusion Requirements
You cannot participate in this study if you are pregnant.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>UC Irvine Medical Center is both a treatment and a research hospital. As a patient here, you may be treated
by some doctors who are also researchers performing studies to improve treatments currently available.

Scientists and clinicians at this institution are working together to discover new ways to treat cancer and
new ways to make current treatments safer and more effective. In order to conduct this research, we need
to study samples of normal and disease tissue obtained from normal volunteers and our patients. In order
to minimize the discomfort and risk to subjects, we are seeking to collect tissue that is left over from studies
that are required for your evaluation and care and are already being done. In certain circumstances (blood
draw and bone marrow aspiration) we are seeking to collect a small amount of tissue in addition to the
sample that would be collected for your routine care. Except for giving samples of blood, you will not be
asked to undergo any procedure solely for the purpose of obtaining a sample for this study. 

You are being asked to take part in this research study because you have or are being evaluated for a
hematologic malignancy, bone marrow disorder, or immune system disorder.

This research study involves the collection and storage of blood and other tissue for later research testing.
It is not currently known how samples donated to the repository will be used at this time. These research tests may be developed during the time you are a patient at UC Irvine Medical Center, or in some cases, years later. Any researcher at UCI or their collaborators (including for-profit entities) may request permission to use samples from the repository. Frozen de-identified samples will be provided to researchers after their plans have been evaluated and approved by the UCI review board that oversees human research (IRB). These tests may provide additional information that will be helpful in understanding cancer and other diseases, but it is unlikely that what we learn from these studies will benefit you directly.

These studies may benefit other patients in the future. The research performed on these samples may
include the study of genetics, including the subject&amp;#8217;s DNA code, parts or the DNA code or even whole
genome sequencing. Samples from the repository will not be used to create cell lines. 

</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Other</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-24T10:07:16</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-15-40</PROTOCOL_NO>
    <TITLE>[EXEMPT - REGISTRY TRIAL] Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma</TITLE>
    <NCT_ID>NCT99999999</NCT_ID>
    <SHORT_TITLE>Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Maki Yamamoto</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>You are eligible to participate in this study if you are at least 18 years old and have a confirmed diagnosis of 
melanoma. </ELIGIBILITY>
    <DETAILED_ELIGIBILITY>You are eligible to participate in this study if you are at least 18 years old and have a confirmed diagnosis of 
melanoma. </DETAILED_ELIGIBILITY>
    <DESCRIPTION>Advances in the treatment of malignant melanoma are being developed in terms of medical information on
diagnosis, surgery, adjuvant therapy and post-treatment surveillance. The purpose of this protocol would be to
create a data repository by collecting key data elements to watch for patterns within melanoma to potentially
help future patients. By collecting this data, we intend to assess trends by watching for patterns of melanoma
inclusive of treatment, criteria for staging, time to recurrence, population, patients at risk for recurrence,
survival of patients, and time to death. The collection of this data will include a retrospective collection of
historical patients and a prospective collection from new patients within the melanoma UC Irvine Health clinics</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Basic Science</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC />
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-12T11:45:58</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ALLIANCE-A071401</PROTOCOL_NO>
    <TITLE>Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations</TITLE>
    <NCT_ID>NCT02523014</NCT_ID>
    <SHORT_TITLE>Ph II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas w/ SMO/ AKT/ NF2 Mutations</SHORT_TITLE>
    <INVESTIGATOR_NAME>Daniela Bota</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Histologically proven intracranial meningioma as documented by 
central pathology review
- Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN 
mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 
copy number gain in tumor sample as documented specifically by the central laboratory
- Male or female who are not pregnant and not nursing

Exclusion Criteria:
- Patients who have active bacterial infection
- Patients who have history of heart diseases as described by the study protocol
- Patients who have uncontrolled hypertension</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-06-17T16:20:02</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Alliance</SPONSOR_NAME>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-16-79</PROTOCOL_NO>
    <TITLE>A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)</TITLE>
    <NCT_ID>NCT03093116</NCT_ID>
    <SHORT_TITLE>Ph I/II Study of TPX-0005 for ALK/ROS1/NTRK1-3 Rearrangements in Adv Solid Tumors (TRIDENT-1)</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you 
&amp;#8226;	Are a male or female subject, 18 years of age or older 
&amp;#8226;	Are able to adhere to the study visit schedule and other protocol requirements
&amp;#8226;	Have a confirmed diagnosis of locally advanced or metastatic solid tumor that has a specific gene rearrangement

Exclusion Requirements 
You cannot participate in this study if you
&amp;#8226;	Are pregnant or breastfeeding, or intending to become pregnant during the study 
&amp;#8226;	Are currently participating in another therapeutic clinical trial
&amp;#8226;	Have a known active infection (bacterial, fungal, or viral, including human immunodeficiency virus positivity).</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study has 2 parts (Phase 1 and Phase 2): 
&amp;#8226;	Phase 1: Phase 1 of this research study is currently ongoing. It was the first time that the study drug, reprotrectinib, was given to humans.
o	The purpose of Phase 1 was to determine the dose of repotrectinib to use in Phase 2 of the study.  Phase 1 look at the side effects and response of tumors to different doses of repotrectinib. Phase 1 also looked at how different foods affect how repotrectinib gets into the body. Phase 1 includes the following sub-studies:
&amp;#61607;	Phase 1a, where the study drug is given under fasting conditions. You will need to fast 1 hour before and 2 hours after study drug administration. As of November 5th 2018, this part of the study is completed and will not enroll any new subjects
&amp;#61607;	Phase 1b is a Food Effect Sub-Study (a study within a study). You may be asked to participate in the Food Effect Sub-Study. The purpose of the Food Effect Sub-Study is to determine the effect of high-fat, high-calorie food on a single dose of repotrectinib (how much and how fast repotrectinib gets into the body after a meal). As of November 5th 2018, this part of the study is completed and will not enroll any new subjects.
&amp;#61607;	Phase 1 also includes a study of repotrectinib when administered continuously with food, where you will take every dose of the study drug with a standard meal, called Phase 1c. 
&amp;#8226;	Phase 2: You are being asked to participate in Phase 2 of this study (not Phase 1). The purpose of Phase 2 is to determine, more specifically, whether repotrectinib works, especially in groups of subjects who have the various tumor gene rearrangements mentioned above. Phase 2 will also continue to look at the side effects as well as how repotrectinib is absorbed into the body.
The Phase 2 portion of the study will evaluate the anti-cancer activity of repotrectinib at the dose listed below:
&amp;#8226;	160 mg once a day for 14 days that may increase to 160 mg twice a day based on the drug&amp;#8217;s tolerability 
The study doctor will assess and decide if your dose should be increased or decreased.
 No study procedures related to this study will be performed until you have signed this Informed Consent Form. A copy of the signed Informed Consent Form will be given to you to keep.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-08T16:27:33</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Turning Point Therapeutics</SPONSOR_NAME>
      <SPONSOR_NAME>INC Research, Inc. (Raleigh, North Carolina)</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-16-56</PROTOCOL_NO>
    <TITLE>Phase II, Single Arm Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent WHO Grade III Malignant Astrocytoma</TITLE>
    <NCT_ID>NCT03450850</NCT_ID>
    <SHORT_TITLE>Ph II Study of Optune in Bevacizumab-Na√Øve Subjects w/ Recurrent WHO Grade III Malignant Astrocytoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Daniela Bota</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults 21 years of age and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
 
Inclusion Requirements
You can participate in this study if you:
1.	Are greater than 21 years of age
2.	Have been diagnosed with brain tumors Anaplastic Astrocytoma (AA)
3.	Have not been treated with Bevacizumab or any anti-angiogenesis drug prior to treatment.

Exclusion Requirements 
You cannot participate in this study if you:
1.	Are pregnant or breastfeeding
2.	Have had chemotherapy within 4 weeks of starting this study
3.	Have any condition the study doctor feels increase the risk to you by participating on this study.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV (Bevacizumab) or any experimental agents.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-12T13:18:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NovoCure Ltd.</SPONSOR_NAME>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-BN003</PROTOCOL_NO>
    <TITLE> Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma</TITLE>
    <NCT_ID>NCT03180268</NCT_ID>
    <SHORT_TITLE>Ph III Trial of Observation Vs Irradiation for a Gross Totally Resected Grade II Meningioma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Xiao-Tang Kong</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- The patient must have a newly diagnosed unifocal intracranial meningioma, gross totally resected, and histologically confirmed as WHO grade II based upon pathology findings at the enrolling institution; WHO grade will be assigned according to WHO 2016 criteria
- Gross total resection (GTR) will be interpreted as modified Simpson grade 1-3 without gross residual dural-based or extradural tumor; GTR must be confirmed both by modified Simpson grade and by post-operative magnetic resonance imaging (MRI) findings
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry

Exclusion Criteria: 
- Definitive evidence of metastatic meningioma
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, cervix, melanoma in situ, or other non-invasive malignancies are permissible)
- Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-26T13:28:34</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ALLIANCE-A071601</PROTOCOL_NO>
    <TITLE>Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas</TITLE>
    <NCT_ID>NCT03224767</NCT_ID>
    <SHORT_TITLE>Ph II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas</SHORT_TITLE>
    <INVESTIGATOR_NAME>Yoon Jae Choi</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Pre-registration: Patients must have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review; central pathology review will include immunohistochemistry (IHC) testing for BRAF V600E mutation (VE1 clone) and beta-catenin IHC (membranous, non-nuclear pattern) if needed to confirm diagnosis of papillary craniopharyngioma
- Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC
- Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =&lt; 7 days prior to registration is required

</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-26T13:45:24</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Alliance</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-21</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).</TITLE>
    <NCT_ID>NCT03157128</NCT_ID>
    <SHORT_TITLE>Ph I/II LOXO-292 for RET Fusion+ Solid Tumors, Medullary Thyroid Ca &amp; Other Tumors w/RET Activation</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Key Inclusion Criteria:

For Phase 1:

Participants with a locally advanced or metastatic solid tumor that:
Has progressed on or is intolerant to standard therapy, or
For which no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or
Decline standard therapy
Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed
A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation
Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type
Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance Score (LPS) greater than or equal to (&amp;#8805;) 40 percent (%) (age less than [&lt;] 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment
Adequate hematologic, hepatic and renal function
Life expectancy of at least 3 months
For Phase 2: As for phase 1 with the following modifications:

For Cohort 1: Participants must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy
Cohorts 1 and 2:

Enrollment will be restricted to participants with evidence of a RET gene alteration in tumor
At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated
Cohorts 3 and 4: Enrollment closed
Cohort 5:

Without measurable disease but otherwise meet criteria for Cohorts 1 and 2;
MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with neuroendocrine features/differentiation, or poorly differentiated thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor approval;
cfDNA positive for a RET gene alteration not known to be present in a tumor sample
Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued another RET inhibitor due to intolerance may be eligible with prior Sponsor approval
Cohort 7: Participants must have a histologically confirmed stage IB-IIIA NSCLC by AJCC (The American Joint Committee on Cancer) version 8. The tumor must have been deemed resectable by a thoracic surgeon, the participant must be determined to be medically operable based on the determination of a thoracic surgeon, and the participant must not have received prior systemic therapy, including prior radiation therapy, for NSCLC.

Key Exclusion Criteria (Phase 1 and Phase 2):

Phase 2 Cohorts 1 and 2: an additional known oncogenic driver
Cohorts 3 and 4: Enrollment closed
Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval
Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is permitted Note: Potential exception for this exclusion criterion will require a valid scientific justification and approval from the Sponsor
Major surgery (excluding placement of vascular access) within 4 weeks prior to planned start of LOXO-292 (selpercatinib)</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T21:24:26</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Loxo Oncology, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Cervix Uteri</DISEASE_SITE>
      <DISEASE_SITE>Bladder</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-64</PROTOCOL_NO>
    <TITLE>An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors</TITLE>
    <NCT_ID>NCT03767348</NCT_ID>
    <SHORT_TITLE>Phase I/II Study of RP1 as a Single Agent &amp; in Combo W/ PD1 Blockade in Pts W/ Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>John P Fruehauf</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult
</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.


Inclusion Requirements 
You can participate in this study if you 
-At least one measurable and injectable lesion
-Have provided a former tumor pathology specimen or be willing to supply a new tumor sample from a biopsy
-Have a predicted life expectancy of &amp;#8805; 3 months
-Subjects with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not considered treatable by surgery including basal cell carcinoma, cutaneous squamous cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma skin cancers (per protocol) for whom anti-PD1/PD-L1 therapy is indicated, or have refused, become intolerant to or have no further therapy options available
-Subjects with anti-PD1 failed cutaneous melanoma: has confirmed progressive disease while on anti-PD1 treatment for at least 8 weeks and documented BRAF mutation status
-Subjects with anti-PD1 failed NSCLC: has confirmed progressive disease after no more than two prior systemic treatments including anti-PD1/PD-L1 treatment

Exclusion Requirements 
You cannot participate in this study if you 
-Prior treatment with an oncolytic therapy
-History of viral infections according to the protocol
-Prior complications with herpes infections
-Chronic use of anti-virals
-Uncontrolled/untreated brain metastasis
-History of interstitial lung disease
-History of non-infectious pneumonitis
-History of clinically significant cardiovascular disease</DETAILED_ELIGIBILITY>
    <DESCRIPTION>RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T13:37:44</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Replimune Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Cervix Uteri</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Bladder</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-78</PROTOCOL_NO>
    <TITLE>A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation</TITLE>
    <NCT_ID>NCT03785249</NCT_ID>
    <SHORT_TITLE>Ph I/II Study of MRTX849 in Pts w/ Adv Solid Tumors w/ KRAS G12C Mutation</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Unresectable or metastatic disease
Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
Adequate organ function

Exclusion Criteria:

History of intestinal disease or major gastric surgery or inability to swallow oral medications
Other active cancer</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T21:20:47</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Mirati Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-84</PROTOCOL_NO>
    <TITLE>A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of Adjuvant Avelumab (anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases</TITLE>
    <NCT_ID>NCT03271372</NCT_ID>
    <SHORT_TITLE>Ph III Trial of Adjuvant Avelumab in Merkel Cell Ca Pts W/ Clinically Detected Lymph Node Metastases</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ling Gao</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>-Medical records or confirmed diagnosis of Merkel Cell Carcinoma metastases in regional lymph node(s)
-Life expectancy of more than 3 years
-Must start study treatment no more than 120 days from date of therapy
-Women of childbearing potential must have a negative serum or urine pregnancy test at screening
-Both male and female subjects must be willing to use highly effective contraception
-Ability to provide informed consent and follow study procedures</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>-Confirmation of the MCC diagnosis in the regional lymph node(s) is mandatory for trial participation
-Estimated life expectancy greater than 3 years
-Must start the study treatment no more than 120 days from the start date of definitive therapy
-Women of childbearing potential must have a negative serum or urine pregnancy test at screening
-Both male and female subjects must be willing to use highly effective contraception
-Must have an ability to understand and the willingness to sign a written informed consent document
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-09T16:29:22</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>University of Washington</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-105</PROTOCOL_NO>
    <TITLE>Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients with Acute Myelogenous Leukemia with MDS Related Changes or Therapy-Related Acute Myeloid Leukemia</TITLE>
    <NCT_ID>NCT04231851</NCT_ID>
    <SHORT_TITLE>PhII Study: Combo Glasdegib&amp;Vyxeos in Pts w/ Ac Myelogeous Leuk w/ MDS or Ac Myeloid Leuk out of MDS</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
- Have previously untreated AML with MDS-related changes or therapy-related AML
- Are 18 years of age or older
- Do not have any unstable heart conditions such as having a heart attack within the past 6
months, uncontrolled heart failure, or uncontrolled irregular heartbeat

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- Previous treatment with either CPX-351 or Glasdegib
- Any active infection or other cancers
- Are pregnant or breastfeeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-12T12:49:37</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
      <SPONSOR_NAME>Jazz Pharmaceuticals, Inc.</SPONSOR_NAME>
      <SPONSOR_NAME>Pfizer Pharmaceutical Inc.</SPONSOR_NAME>
      <SPONSOR_NAME>UC Hematologic Malignancies Consortium</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-128</PROTOCOL_NO>
    <TITLE>A Phase I Open-Label, Dose Escalation Study of Pitavastatin in Combination with Venetoclax in Patients with Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia</TITLE>
    <NCT_ID>NCT04512105</NCT_ID>
    <SHORT_TITLE>A Phase I Study of Pitavastatin in Combination with Venetoclax for CLL or AML</SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined;the study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria: 
- At least 18 years of age
- Confirmed diagnosis of CLL or AML
- You are starting treatment with a regimen that includes VEN and are on a stable dose of VEN

Exclusion Requirements 
You cannot participate in this study if you have any of the following criteria:
- Are pregnant or nursing
- Unable to swallow pills 
- Have received any investigational agents during the previous 30 days or will be receiving any other investigational agents at any time during the study.

</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax (VEN) in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). These are subjects who are newly diagnosed subjects with AML who are ineligible for intensive induction chemotherapy, relapsed/refractory CLL or newly diagnosed CLL.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-28T15:49:11</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
      <SPONSOR_NAME>Department of Defense</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-18-136</PROTOCOL_NO>
    <TITLE>Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer</TITLE>
    <NCT_ID>NCT99999999</NCT_ID>
    <SHORT_TITLE>Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

You can participate in this study if you:
- Are female
- Over the age of 18
- Ability to understand and the willingness to sign a written informed consent document
- Consent to be in the study, signed and dated an approved consent form, which conforms to federal and institutional guidelines.
- For cancer patients, you must have either Stage I, Stage II, Stage III or Stage IV Breast cancer
- For cancer patients, you must have either hormone Receptor +, Her-2 receptor positive, triple
positive or triple negative breast cancer

Exclusion Requirements
You cannot participate in this study if you
- Are physically or mentally incapable to give verbal or written consent
- For cancer patients: have other active cancers expect for cured skin and in situ cervical cancer
- For non-cancer participants: history of cancer diagnosis or prior exposure to chemotherapy
agents</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Scientists and clinicians at this institution are working together to discover new ways to monitor cancer
and find tests that could detect recurrence early on. The purpose of this research study is to determine
a group of particles in the blood called exosomes that may be associated with response to treatment
or could predict recurrence and side effects.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Basic Science</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-01T13:51:12</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
      <SPONSOR_NAME>Hitachi Chemical Research Center</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ALLIANCE-N0577</PROTOCOL_NO>
    <TITLE>Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma</TITLE>
    <NCT_ID>NCT00887146</NCT_ID>
    <SHORT_TITLE>Ph III: Radio w/ Concom &amp; Adj TMZ vs. Radio w/ Adj PCV Chemo in Pts w/ 1p/19q Anapl. or Low-g Glioma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Xiao-Tang Kong</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Histological evidence of WHO grade III anaplastic glioma or WHO grade II low grade glioma 
- Surgery (partial or gross total resection or biopsy) must be performed more than 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery.
- Willingness and ability to personally complete neurocognitive testing (without assistance) and willingness to complete the QOL testing, (either personally or with assistance)

Exclusion Criteria: 

- Pregnant and/or nursing women
- Subjects of childbearing potential who are unwilling to employ adequate contraceptive method during treatment and 6 months after chemotherapy treatments
- Immunocompromised patients or HIV Positive Patients Receiving Retroviral Medications</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-25T13:31:12</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Alliance</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-49</PROTOCOL_NO>
    <TITLE>Phase II Study of Cabozantinib Combined with Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) Who are not Candidates for Curative Intent Treatment</TITLE>
    <NCT_ID>NCT04472767</NCT_ID>
    <SHORT_TITLE>Ph II of Cabo. w/ Ipi./Nivo. and TACE in Pts w/ HCC (not candidates for Curative Tx)</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy following criteria:
- At least 18 years of age
- Biopsy proven or imaging based diagnosis of hepatocellular carcinoma ("primary liver cancer")
- Not a candidate for surgery or curative treatment based on your doctor's assessment

Exclusion Requirements
You cannot participate in this study if you have any of the following criteria:
- Previous treatment with cabozantinib or immunotherapy
- Any active infection (except for controlled Hepatitis B or C) or other cancers
- Pregnant or nursing</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-07T17:16:04</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
      <SPONSOR_NAME>Exelixis, Inc. </SPONSOR_NAME>
      <SPONSOR_NAME>Anti Cancer Challenge Grant</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-55</PROTOCOL_NO>
    <TITLE>A Non-Interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Solid Tumors Including Gastric and Gastroesophageal Junction Adenocarcinoma</TITLE>
    <NCT_ID />
    <SHORT_TITLE>A Non-Interventional Biomarker Study on the Molecular Evaluation of Tumor Tissue in Pts w/ GastricCa</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Patients with histologically or cytologically confirmed locally advanced or metastatic gastric adenocarcinoma or GEJ adenocarcinoma at the time of enrollment.
- Patients who have available archival tumor tissue sample from biopsy or tumor resection not older than 20 years and adequate for central laboratory testing of MUC17 and CLDN18.2, with corresponding pathology report. 

Exclusion Criteria:

- There are no exclusion criteria for this study as long as the subject meets all inclusion criteria.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this research study is to study previously collected tumor tissue that will help in identifying potential patients with MUC17 and/or CLDN18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.. The results of this study may be used later for the identification of subjects who may be referred to interventional studies at UCI with investigational drugs, AMG 199 or AMG 910. </DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Screening</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-12-07T08:37:35</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S1806</PROTOCOL_NO>
    <TITLE>Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer</TITLE>
    <NCT_ID>NCT03775265</NCT_ID>
    <SHORT_TITLE>Ph III Trial of Concurrent Chemoradiation w/ or w/o Atezolizumab for Localized MIBC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ramy Yaacoub</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Histologically proven urothelial carcinoma of the bladder within 120 days prior to the start of  the study
- No prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor
- No clinically significant liver disease, including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, or inherited liver disease.

Exclusion Criteria:

- Major surgical procedure within 28 days prior to the start of the study
- Patients who have received a live, attenuated vaccine (such as a flu shot) within 4 weeks prior to participation
- Patients with active infection requiring oral or IV antibiotics within 14 days prior to participation
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-22T10:48:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-64</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors</TITLE>
    <NCT_ID>NCT02912949</NCT_ID>
    <SHORT_TITLE>Ph I/II Study of MCLA-128, IgG1 Bispecific Antibody Targeting HER2 &amp; HER3, in Pts w/ Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 10) in Group H;
Performance status of ECOG 0 or 1;
Estimated life expectancy of at least 12 weeks;
Toxicities incurred as a result of previous anti-cancer therapy resolved to &amp;#8804;Grade 1;
Treatment with anti-cancer medication or investigational drugs within the following intervals before the first dose of MCLA-128:

&gt;14 days or &gt;5 half-lives prior to study entry, whichever is shorter.
&gt;14 days for radiotherapy.
Recovery from major surgery or other complication to &amp;#8804; Grade 2 or baseline ;
Absolute neutrophil count &amp;#8805;1.5 x 109/L without colony stimulating factor support;
Platelets &amp;#8805;100 x 109/L;
Hemoglobin &amp;#8805;8 g/dL or &amp;#8805;2.2 mmol/L;
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) &amp;#8804;3 x upper limit of normal (ULN) and total bilirubin &amp;#8804;1.5 x ULN; in cases of metastatic liver involvement, ALT/AST &amp;#8804;5 x ULN and total bilirubin &amp;#8804;2 x ULN will be allowed; in cases of antecedents of Gilbert's syndrome when total bilirubin &amp;#8804;3.0 x ULN or direct bilirubin &amp;#8804;1.5 x ULN will be allowed;
Estimated glomerular filtration rate (GFR) of &gt;30 mL/min
Able to provide a tumor biopsy sample (fresh strongly preferred or else archival);
Not pregnant or nursing

Exclusion Criteria:

Pregnant or lactating;
Presence of an active uncontrolled infection or an unexplained fever;
Known hypersensitivity to any of the components of MCLA-128;
Known HIV, active Hepatitis B or Hepatitis C; patients treated for Hepatitis C and have undetectable viral loads are eligible
Known symptomatic or unstable brain metastases;
Patients with leptomeningeal metastases
Presence of congestive heart failure or Left Ventricular Ejection Fraction&lt;50% or history of significant cardiac disease, unstable angina, myocardial infarction or ventricular arrhythmia requiring medication.
Previous or concurrent malignancy (excluding non-basal cell carcinoma of skin or carcinoma in situ of the uterine cervix) unless the tumor was treated with curative intent more than 2 years prior to study entry;
Presence of any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T20:48:16</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Merus N.V. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-65</PROTOCOL_NO>
    <TITLE>A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation</TITLE>
    <NCT_ID>NCT03974022</NCT_ID>
    <SHORT_TITLE>Ph I/II, Study of DZD9008 in Pts w/ Adv Non-Small Cell Lung Cancer (NSCLC) w/ EGFR or HER2 Mutation</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Aged at least 18 years old (&amp;#8805; 20 if in Japan), be able to provide a signed and dated, written informed consent.
With documented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.
(ECOG) performance status 0-1.
Predicted life expectancy &amp;#8805; 12 weeks
Patient must have measurable disease according to RECIST 1.1.
Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.
Adequate organ system function.
Exclusion Criteria:

For part B: Patients who have received prior treatment with Poziotinib or TAK788 or other EGFR/HER2 exon20 insertion inhibitors should be excluded. Prior treatment with currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as gefitinib, erlotinib, osimertinib, afatinib and dacomitinb, are allowed.
Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular access), or onco-immunotherapy (e.g. immune checkpoint inhibitors PD-1, PD-L1, CTLA-4) within 4 weeks before screening.
Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before screening.
Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before screening.
Receiving (or unable to stop using) medications or herbal supplements known to be potent inhibitors or inducers of CYP3A within 2-3 weeks before screening.
Grapefruit, grapefruit juice, and orange marmalade (made with Seville oranges) within 1 week before screening.
Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting DZD9008 with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
Spinal cord compression or leptomeningeal metastasis.
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Any of the following cardiac criteria: (1) Mean resting corrected QT interval (QTcF) &gt; 470 msec obtained from 3 electrocardiograms (ECGs); (2) Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval &gt; 250 msec. (3) Any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD9008
History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with a similar chemical structure or class to DZD9008</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T20:42:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Dizal (Jiangsu) Pharmaceutical Co., Ltd</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>A071701</PROTOCOL_NO>
    <TITLE>Genetic Testing in Guiding Treatment for Patients with Brain Metastases</TITLE>
    <NCT_ID>NCT03994796</NCT_ID>
    <SHORT_TITLE>Genetic Testing in Guiding Treatment for Patients with Brain Metastases</SHORT_TITLE>
    <INVESTIGATOR_NAME>Yoon Jae Choi</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Pre-registration Eligibility:

- Tissue available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy)

Registration Eligibility:

- Participants must have histologically confirmed parenchymal metastatic disease to the brain from any solid tumor
- Female participants must not be pregnant or breastfeeding
- Ability to obtain MRIs with contrast
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-04-21T09:36:35</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Alliance</SPONSOR_NAME>
      <SPONSOR_NAME>Alliance for Clinical Trials in Oncology</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-93</PROTOCOL_NO>
    <TITLE>Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage</TITLE>
    <NCT_ID>NCT03926624</NCT_ID>
    <SHORT_TITLE>Ph III Study DFP-10917 vs. Non-Intensive or Intensive Reinduction for AML Pts in 2nd or 3rd Salvage</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you
-  must be able to sign the informed consent prior to the start of any study specific procedures.

Exclusion Requirements

You cannot participate in this study if you
-  pregnant or lactating woman.
-  have  known human immunodeficiency virus (HIV), active Hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection

</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with Acute myeloid leukemia (AML) relapsed/refractory after 2, 3, or 4 prior induction regimens:

Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m¬≤/day followed by a 14-day resting period per 28-day cycles.

Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-01T08:59:34</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Delta-Fly Pharma, Inc. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-19-145</PROTOCOL_NO>
    <TITLE>Phase II, Open-Labeled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer </TITLE>
    <NCT_ID>NCT05524584</NCT_ID>
    <SHORT_TITLE>Ph II Trial of Anastrazole, Fulvestrant &amp; Abemaciclib for HR+HER2- Metastatic Breast Cancer </SHORT_TITLE>
    <INVESTIGATOR_NAME>Rita Mehta</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult, Older Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
&amp;#61623; Are at least 18 years of age
&amp;#61623; Have a diagnosis of hormone receptor positive (HR+) breast cancer
&amp;#61623; Are able to swallow oral medications

Exclusion Requirements
You cannot participate in this study if you
&amp;#61623; Are pregnant or nursing
&amp;#61623; Are receiving an investigational drug in other clinical trials
&amp;#61623; Have an active bacterial or fungal infection</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects who have progressed following treatment free interval of more than 12 months following adjuvant or neoadjuvant treatment.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-01T14:47:56</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-GI005</PROTOCOL_NO>
    <TITLE>Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) </TITLE>
    <NCT_ID>NCT04068103</NCT_ID>
    <SHORT_TITLE>Phase II/III, Circulating Tumor DNA as Predictive Biomarker in Adj Chemo in Pts w/Stage IIA Colon Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jason Zell</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
You must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically/pathologically confirmed stage IIA adenocarcinoma of the colon (T3, N0, M0) with at least 12 lymph nodes examined at the time of surgical resection.
Appropriate for active surveillance (i.e., no adjuvant chemotherapy) at the discretion of and as documented by the evaluating oncologist based on current practice patterns.
The distal extent of the tumor must be &gt;= 12 cm from the anal verge on pre-surgical endoscopy (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation). If the patient did not undergo a pre-surgical endoscopy, then the distal extent of the tumor must be &gt;= 12 cm from the anal verge as determined by surgical examination or pre-operative imaging.
You must have had an en bloc complete gross resection of tumor (curative resection) as definitive surgical cancer treatment within 14 to 60 days of study randomization. Patients who have had a two-stage surgical procedure to first provide a decompressive colostomy and then, in a later procedure, to have the definitive surgical resection, are eligible.
Availability and provision of adequate surgical tumor tissue for molecular diagnostics and confirmatory profiling.

Exclusion Criteria:
Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).
Pathologic, clinical, or radiologic evidence of overt metastatic disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected (including the presence of satellite nodules constituting N1c disease in the absence of lymph node involvement).
Tumor-related bowel perforation.
History of prior invasive colon malignancy, regardless of disease-free interval.
History of organ transplantation.
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary rectal adenocarcinomas for which treatment with neoadjuvant chemoradiation is warranted are not permitted).
Other invasive malignancy within 5 years before randomization. Exceptions are colonic polyps, non-melanoma skin cancer or carcinoma-in-situ including those of the cervix and breast (DCIS).
Synchronous primary rectal and/or colon cancers.
Antineoplastic therapy (e.g., chemotherapy, targeted therapy, or immunotherapy) within 5 years before randomization. (For the purposes of this study, hormonal therapy is not considered chemotherapy.).</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T10:25:13</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>EA2182</PROTOCOL_NO>
    <TITLE>A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)</TITLE>
    <NCT_ID>NCT04166318</NCT_ID>
    <SHORT_TITLE>Ph II Study De-Intensified ChemoRadiation Early-Stage Anal Squamous Cell Carcinoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>Jason Zell</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

- Patient must have diagnosed anal cancer with tumors measuring less than or equal to 4 cm within 4 weeks prior to registration. 
- Patient's tumor size must be documented on physical examination including digital rectal exam and/or anoscopy/proctoscopy within 4 weeks prior to Step 0 pre-registration.
- Patient must have no history of prior radiation or chemotherapy for carcinoma of the anus.
- Patient must not have had prior potentially curative surgery (i.e. abdominal-perineal resection) for carcinoma of the anus.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-11T15:56:51</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Anus</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-31</PROTOCOL_NO>
    <TITLE>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects &lt;=75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma</TITLE>
    <NCT_ID>NCT04529772</NCT_ID>
    <SHORT_TITLE>PhIII Rituxima Cyclophosphamid Doxorubicin Vincristin Prednison v inComb w/Acalabrutini NonGermDLBCL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are between the ages &amp;#8805;18 and &amp;#8804;75 years at the time of screening
- are male or female

Exclusion Requirements
You cannot participate in this study if you
- are a female  who is currently pregnant (confirmed with positive pregnancy test) or breastfeeding </DETAILED_ELIGIBILITY>
    <DESCRIPTION>Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects &amp;#8804;75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-22T14:27:44</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Acerta Pharma BV</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-34</PROTOCOL_NO>
    <TITLE>A Phase IV, Multi-Center Open-Label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects with Minimal Residual Disease (MRD) of B-Precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission</TITLE>
    <NCT_ID>NCT04506086</NCT_ID>
    <SHORT_TITLE>Ph IV Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects w/ MRD of B-precursor ALL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult subjects</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- age &amp;#61619; 18 years in age
- must have negative pregnancy test of you are  women of childbearing potential.


Exclusion Requirements
You cannot participate in this study if you
- are currently receiving treatment with an investigational device or drug study or less than 30 days 
since ending treatment on an investigational device or drug study(ies)
- have no cellular service at home</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to determine the safety and feasibility of outpatient blinatumomab administration for subjects with Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia.</DESCRIPTION>
    <PHASE_DESC>IV</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-14T11:33:57</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-43</PROTOCOL_NO>
    <TITLE>Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas</TITLE>
    <NCT_ID>NCT04920032</NCT_ID>
    <SHORT_TITLE>Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help subjects better understand how their eligibility in the study will be determined; the study team will go through the study eligibility criteria with the subject to verify if they qualify for participation in this study.

Inclusion Requirements
Subjects can participate in this study if they satisfy the following criteria:
- At least 18 years of age
- Confirmed diagnosis of adenocarcinoma (cancer) of the colon
- Positive ctDNA assay (test)

Exclusion Requirements
Subjects cannot participate in this study if they have any of the following criteria:
- Previous treatment with either irinotecan or TAS-102
- Any active infection or other cancers
- Pregnant or nursing</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-24T12:28:07</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
      <SPONSOR_NAME>Taiho Pharmaceuticals</SPONSOR_NAME>
      <SPONSOR_NAME>Natera, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-51</PROTOCOL_NO>
    <TITLE>A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ¬± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients</TITLE>
    <NCT_ID>NCT04372433</NCT_ID>
    <SHORT_TITLE>Ph I IO-202 inCombo w/ Azacitidine in Relap/Ref AML w/ Monocytic Differentiation &amp; in Relap/Ref CMML</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you
-  must be &amp;#8805;18 years old.
-  must be able to understand and willing to sign an informed consent.

Exclusion Requirements

You cannot participate in this study if you
-  must not be pregnant or breast feeding.
-  must not have Active bacterial, viral, and/or fungal infection including hepatitis B (HB), hepatitis C, human immunodeficiency virus (HIV), 
   SARS-CoV-2, or acquired immunodeficiency syndrome (AIDS)-related illness.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-01T09:02:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Immune-Onc Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-67</PROTOCOL_NO>
    <TITLE>A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications</TITLE>
    <NCT_ID>NCT04143711</NCT_ID>
    <SHORT_TITLE>Ph I/II DF1001 in Pts w/ Locally Adv or Metastatic Solid Tumors, &amp; Expansion in Selected Indications</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

Inclusion Criteria:
- Male or female patients at least 18 years of age
- Patients must have histologically or cytologically proven locally advanced or metastatic solid tumors with documented HER2 expression.

Exclusion Criteria:
- Patients must not have had receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation.
- Significant acute or chronic infections (including positive test for HIV), or active or latent hepatitis B or active hepatitis C.
- Serious cardiac illness or medical conditions.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase I/II study to see whether the study drug DF1101, is safe and tolerable for patients with locally advanced or metastatic solid tumors. Patients will be enrolled into 1 of 2 parts: Dose Escalation or Efficacy Expansion. 

Dose Escalation: The main purpose of this part is to test different doses of the study drug, starting with the lowest dose and up to the highest dose. If the dose is considered safe, another group of patients will join the study to receive the study drug at a higher dose.

Efficacy Expansion: The main purose of this part is to further test the selected dose of the study drug in subjects with bladder cancer, breast cancer, or cancers that have high levels of a protein called HER2. Patients in this part of the study will receive the study drug DF1001 alone.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-25T12:27:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Dragonfly Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-76</PROTOCOL_NO>
    <TITLE>University of California COVID-19 and Cancer Registry and Outcomes Project</TITLE>
    <NCT_ID />
    <SHORT_TITLE>University of California COVID-19 and Cancer Registry and Outcomes Project</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY />
    <DESCRIPTION />
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Other</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Both</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-23T16:15:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UC San Francisco </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-79</PROTOCOL_NO>
    <TITLE>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus Liver)</TITLE>
    <NCT_ID>NCT04524871</NCT_ID>
    <SHORT_TITLE>Ph Ib/II Study Evaluating Immuno-based Tx Combin in Pt w/ Adv Liver Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically
- Disease that is not amendable to curative surgical and/or locoregional therapy
- No prior systemic treatment (including systemic investigational drugs) for HCC

Exclusion Criteria:

- Treatment with locoregional therapy to liver (e.g., radiofrequency ablation,
percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused
ultrasound, transarterial chemoembolization, transarterial embolization, etc.) within
28 days prior to initiation of study treatment, or non-recovery from side effects of any
such procedure
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to initiation of study treatment; or abdominal surgery, abdominal interventions
or significant abdominal traumatic injury within 60 days prior to initiation of study
treatment; or anticipation of need for major surgical procedure during the course of
the study or non-recovery from side effects of any such procedure
- Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to
initiation of study treatment with the exception of palliative radiotherapy to bone
lesions within 7 days prior to initiation of study treatment</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.

Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-09T17:17:27</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>F. Hoffmann-La Roche Ltd</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-87</PROTOCOL_NO>
    <TITLE>Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis.</TITLE>
    <NCT_ID>NCT04762953</NCT_ID>
    <SHORT_TITLE>Ph II Trial of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Cancer </SHORT_TITLE>
    <INVESTIGATOR_NAME>Maheswari Senthil</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

Inclusion Criteria:
- Patients must have confirmed primary gastric or gastroesophageal cancer and have received a minimum of 3 months of first line treatment without visceral (liver, lung, brain) metastases. 
- Patients must have peritoneal cytology positive disease or peritoneal carcinomatosis.


Exclusion Criteria:
- Patients must not have had systemic treatment for unresectable or metastatic disease for more than 3 months prior to enrollment.
- Patients must not have any evidence of distant, solid organ metastes (visceral (liver, lung, brain), bone, extra-abdominal).
- Patients must not have any evidence of small or large bowel obstruction with the exception of gastric outlet obstruction due to primary malignancy.
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this research study is to see if sequential intravenous chemotherapy followed by intraperitoneal chemotherapy with paclitaxel combination is safe and will improve cancer control in patients who have gastric cancer that is spread in the abdominal lining ( peritoneum) called peritoneal carcinomatosis (PC). Currently, patients with gastric cancer who have cancer spread to the abdominal lining are only treated with intravenous chemotherapy, which is chemotherapy administered through the vein into the body. We are proposing to add intraperitoneal chemotherapy (chemotherapy infused into the abdominal cavity through a small access device implanted into the abdominal fat tissue) to the usually used intravenous chemotherapy, to study if this combination improves survival in patients.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC />
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-30T15:18:06</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-101</PROTOCOL_NO>
    <TITLE>Prospective Study to Assess the Role of Plasma Exosomal Gene Signature and PD-L1 Expression to Predict Response to Treatment in Solid Organ Malignancies</TITLE>
    <NCT_ID />
    <SHORT_TITLE>PD-L1 to Predict Response to Immune Checkpoint Inhibition in Melanoma &amp; Solid Organ Malignancies</SHORT_TITLE>
    <INVESTIGATOR_NAME>Maheswari Senthil</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>-Male and Female Adults ages 18 and above
-Able to provide consent and follow procedures
-Medical records confirming diagnosis of melanoma, malignant solid tumors</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Ability to understand and the willingness to sign a written informed consent
-Patients must have immunotherapy na√Øve histologically, radiologically, or cytologically confirmed cancer (
Melanoma, HCC, colorectal, appendix or gastric cancer).
-Must have measurable disease at the time of enrollment
-Life expectancy of greater than 6 months
-Adequate organ and marrow function per lab results / values

Exclusion Criteria
-Patient who have received immunotherapy prior to enrollment
-Known active secondary malignancy except for basal cell carcinoma, low grade ( Gleason &lt;6) prostate cancer
and cervical carcinoma in-situ
-Inability to comply with study and follow-up procedures as judged by the Investigator
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 2 prospective study to to evaluate a blood test from patients with solid organ malignancies to predict
response to treatment.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Basic Science</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-23T14:56:31</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S1823</PROTOCOL_NO>
    <TITLE>A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors</TITLE>
    <NCT_ID>NCT04435756</NCT_ID>
    <SHORT_TITLE>Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Arash Rezazadeh Kalebasty</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Pathologically or serologically confirmed diagnosis of a Germ Cell Tumor
- Patients mush have initial imaging, laboratory, and other clinical evaluations performed within 42 days prior to registration
- Risk of relapse assessment determined by the investigator prior to registration

Exclusion Criteria:

- Registration outside of the 42-day window after diagnosis
- Patients who do not agree to submit required specimens for defined translational medicine studies
- Patients who do not have beta-human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase assessments within 42 days prior to registration.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Basic Science</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T09:35:49</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-119</PROTOCOL_NO>
    <TITLE>An Open-Label Phase I/Ib Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations with JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer</TITLE>
    <NCT_ID>NCT04077463</NCT_ID>
    <SHORT_TITLE>Ph I/Ib JNJ-73841937 (Lazertinib) Monotherapy or in Combo w/ JNJ-61186372 Pts w/ Advanced NSCLC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Phase 1 and Phase 1b lazertinib+Amivantamab combination cohorts: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with previously epidermal growth factor receptor (EGFR) mutation (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent]) that is metastatic or unresectable, and have progressed after standard of care front-line therapy, and exhausted available options with targeted therapy. A participant who has refused all other currently available therapeutic options is allowed to enroll
For the Phase 1b Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP) combination cohort: histologically or cytologically confirmed advanced or metastatic EGFR-mutated NSCLC who have progressed on or after an EGFR-TKI as the most recent line of treatment with a maximum of 3 prior lines of therapy in the metastatic setting allowed
For all expansion cohorts, the EGFR mutation must have been previously histologically or cytologically characterized, as performed by a CLIA-certified (US sites) or an accredited (outside of US) local laboratory, with a copy of the mutation analysis being submitted during screening (Phase 1b expansion Cohort B, C and D)

Exclusion Criteria:

Participant has an uncontrolled illness, including but not limited uncontrolled diabetes, ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics week prior to study treatment] or diagnosed or suspected viral infection); active bleeding diathesis; Impaired oxygenation requiring continuous oxygen supplementation; Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of study treatment; or psychiatric illness or any other circumstances including (social circumstances) that would limit compliance with study requirements. Any ophthalmologic condition that is either clinically unstable or requires treatment
Prior treatment with antiPD-1 or anti Programmed death-ligand 1 (PD-L1) antibody within 6 weeks of planned first dose of study intervention
Untreated brain or other central nervous system (CNS) metastases whether symptomatic or asymptomatic. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment may be eligible for Phase 1b expansion cohorts. If brain metastases are diagnosed on Screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B and C), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B and C), to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T20:31:42</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Janssen Research &amp; Development, LLC</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-123</PROTOCOL_NO>
    <TITLE>An Open-Label, Randomized, Phase III Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy</TITLE>
    <NCT_ID>NCT04586231</NCT_ID>
    <SHORT_TITLE>Ph III MK-6482 in Combo w/ Lenvatinib vs Cabozantinib in Pts w/ Adv Renal Cell Carcinoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>Arash Rezazadeh Kalebasty</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).
- Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment with progression on or within 6 months of last dose.
- Received no more than 2 prior systemic regimens.

Exclusion Criteria:

- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Clinically significant cardiac disease within 6 months of first dose of study intervention.
- Currently participating in a study of an investigational agent or using an investigational device.
- History of human immunodeficiency virus (HIV) infection.
- History of hepatitis B or known active hepatitis C infection.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-03-23T10:17:34</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Merck Sharp &amp; Dohme Corp.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-126</PROTOCOL_NO>
    <TITLE>A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)</TITLE>
    <NCT_ID>NCT04637763</NCT_ID>
    <SHORT_TITLE>Ph I CB-010 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Ptsw/ R/R Non-Hodgkin Lymphoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>Susan O'Brien</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
&amp;#61623; Are at least 18 years old
&amp;#61623; Understand and are willing to sign informed consent.

Exclusion Requirements  
You cannot participate in this study if you
&amp;#61623; Are pregnant or breastfeeding
&amp;#61623; Have history of infection with human immunodeficiency virus (HIV)
&amp;#61623; Have active hepatitis B or C virus infection
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-24T10:16:52</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Caribou Biosciences, Inc. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-127</PROTOCOL_NO>
    <TITLE>A Phase III Randomized Placebo controlled Double-Blind Study of Romiplostim for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer</TITLE>
    <NCT_ID>NCT03362177</NCT_ID>
    <SHORT_TITLE>Ph III, Romiplostim for the Tx of Chemo-Induced Thrombocytopenia in Pts Receiving FOLFOX-Based Chemo</SHORT_TITLE>
    <INVESTIGATOR_NAME>Zahra Pakbaz</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant </DETAILED_ELIGIBILITY>
    <DESCRIPTION>Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-17T18:26:39</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-133</PROTOCOL_NO>
    <TITLE>Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities</TITLE>
    <NCT_ID>NCT04683250</NCT_ID>
    <SHORT_TITLE>Ph I/II Selective RET Inhibitor TAS0953/HM06 in Pts w/ Adv Solid Tumors with RET Gene Abnormalities</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Phase I - Common inclusion criteria for Dose-Escalation / Dose-Expansion:

Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
Available RET-gene abnormalities determined on tissue or liquid biopsy
Documented progression of disease following existing therapies deemed by the Investigator to have demonstrated clinical benefit or unable to receive such therapies.
Adequate hematopoietic, hepatic and renal function
Phase I Dose-Escalation - Specific inclusion criteria:

Advanced solid tumors
Measurable and/or non-measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases, (s)he should be asymptomatic.
Phase I Dose-Expansion - Specific inclusion criteria:

Locally advanced or metastatic non small cell lung cancer (NSCLC) patients with primary RET gene fusion and prior exposure to RET selective inhibitors
Measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases,(s)he should have:

asymptomatic untreated brain/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or
asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.
Phase II :

Available RET-gene abnormalities determined on tissue or liquid biopsy
Locally advanced or metastatic:

NSCLC patients with primary RET gene fusion and prior exposure to RET selective inhibitors;
NSCLC patients with RET gene fusion and without prior exposure to RET selective inhibitors
patients with advanced solid tumors that harbour RET gene abnormalities (other than NSCLC patients with primary RET gene fusions) and has failed all the available therapeutic options
Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
Measurable disease as determined by RECIST 1.1
If patient has brain and/or leptomeningeal metastases,(s)he should have:

asymptomatic untreated brain/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or
asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.
Adequate hematopoietic, hepatic and renal function
Exclusion Criteria:

Common exclusion criteria for Phase 1 and Phase 2

Investigational agents or anticancer therapy within 5 half-lives prior to the first dose of study drug
Major surgery (excluding placement of vascular access) within 4 weeks prior to the first dose of study drug or planned major surgery during the course of study treatment.
Whole Brain Radiotherapy within 14 days or other palliative radiotherapy within 7 days prior to the first dose of study drug, or persisting side effects of such therapy, in the opinion of the Investigator.
Clinically significant, uncontrolled, cardiovascular disease including myocardial infarction within 3 months prior to Day 1 of Cycle 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension, according to the Investigator's opinion.
QT interval corrected using Fridericia's formula (QTcF) &gt;470 msec; personal or family history of prolonged QT syndrome or history of Torsades de pointes (TdP). History of risk factors for TdP
Treatment with strong CYP3A4 inhibitors within 1 week prior to the first dose of study drug or strong CYP3A4 inducers within 3 weeks prior to the first dose of study drug.
Phase I Dose-Expansion - and Phase II specific exclusion criteria:

Presence of known EGFR, KRAS, ALK, HER2, ROS1, BRAF and METex14 activating mutations.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-27T09:17:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Taiho Pharmaceuticals</SPONSOR_NAME>
      <SPONSOR_NAME>Helsinn Healthcare SA</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10057</PROTOCOL_NO>
    <TITLE>A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors</TITLE>
    <NCT_ID>NCT02978625</NCT_ID>
    <SHORT_TITLE>Ph II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab Skin Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Maki Yamamoto</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults, Older Adults
</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>-18 Yrs old and over
-Ability to understand and the willingness to sign a written informed consent document.
-Must histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas
-Untreated central nervous system (CNS) involvement; patients with known brain metastases are eligible
-Must be able and willing to undergo serial biopsies of injected lesion(s)
-Women of child-bearing potential (WOCBP) and must agree to use adequate contraception</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T09:34:03</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10264</PROTOCOL_NO>
    <TITLE>The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome</TITLE>
    <NCT_ID>NCT03953898</NCT_ID>
    <SHORT_TITLE>Ph II Study of Olaparib in Isocitrate Dehydrogenase Mutant R/R AML and Myelodysplastic Syndrome</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) per World Health Organization 2016 classification. AML may be de novo, or following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related.
- Patients must have a documented IDH1 or IDH2 mutation within 30 days of inclusion
based on mutational testing. Only specific mutations that lead to a neomorphic
phenotype will be eligible for enrollment
- Patients with AML or MDS should have disease that has relapsed after, or is refractory
to, first-line therapy, with or without subsequent additional therapy.

Exclusion Criteria:
- Patients with acute promyelocytic leukemia.
- Patients with active central nervous system (CNS) leukemia or requiring maintenance
intrathecal chemotherapy.
- Patients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for
AML/MDS.
- Patients actively receiving any other investigational agents.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well olaparib works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or myelodysplastic syndrome. Patients must also have a change in the gene called the IDH gene (IDH mutation). Olaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to see if olaparib is better or worse in treating acute myeloid leukemia or myelodysplastic syndrome compared to the standard chemotherapy drugs.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2020-11-16T17:50:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10146</PROTOCOL_NO>
    <TITLE>Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer</TITLE>
    <NCT_ID>NCT03606967</NCT_ID>
    <SHORT_TITLE>Ph II Nab-Paclitaxel+Durvalumab+Tremelimumab + Neoantigen Vaccine in Pts w/ Met Triple Neg Breast Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer.
- Must have a life expectancy of at least 12 weeks.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria: 
- Patients who are not considered to be candidates for carboplatin + gemcitabine for first line therapy of their metastatic triple negative breast cancer are not eligible.
- Patients who have had chemotherapy, radiotherapy (to more than 30% of the bone marrow), or biologic therapy within 30 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.
- Patients who have received prior immunotherapy for metastatic disease.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-24T11:21:55</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10302</PROTOCOL_NO>
    <TITLE>Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer</TITLE>
    <NCT_ID>NCT04090398</NCT_ID>
    <SHORT_TITLE>Ph II Radium-223 Dichloride in Combination w/ Paclitaxel in Patients w/ Bone Metastatic Breast Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Women or men with metastatic breast cancer with two or more bone metastases identified by technetium Tc-99m (99mTc) bone scintigraphy and/or computed tomography (CT), at least one of these bone lesions must not have been treated with prior radiation therapy
-A diagnosis of breast cancer must have been histologically or cytologically confirmed at any time point

Exclusion Criteria:
-Patients with peripheral neuropathy &gt; grade 1
-Patients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities &gt; grade 1) with the exception of alopecia
-Prior therapy with radionuclides (e.g., strontium, samarium, rhenium, radium)

</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones. Radium-223 dichloride is a radioactive drug that behaves in a similar way to calcium and collects in cancer that has spread to the bones (bone metastases). The radioactive particles in radium-223 dichloride act on bone metastases, killing the tumor cells and reducing the pain that they can cause. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radium-223 dichloride and paclitaxel may work better in treating patients with metastatic breast cancer compared to paclitaxel alone</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-07-09T17:45:49</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10366</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma</TITLE>
    <NCT_ID>NCT04172532</NCT_ID>
    <SHORT_TITLE> Ph I/II Peposertib in Combo w/Hypofractionated Radiotherapy for Tx of Adv Pancreatic Adenocarcinoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Patients must have pathologically confirmed pancreatic adenocarcinoma.
- Patients must have received 4-6 months of induction chemotherapy with either FOLFIRINOX or gemcitabine/abraxane, as per standard of care.
- Patients must have locally advanced pancreatic cancer according to NCCN Guidelines on CT scan performed within 21 days of registration.

Exclusion Criteria:

- Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment.
- Patients who are participating in other clinical trials and receiving any other investigational treatment.
- Patients who have evidence of distant metastatic disease.
- Patients who have had more than 1 line of chemotherapy for the treatment of localized pancreatic cancer.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase I/II trial studies the side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that cannot be removed by surgery and has not spread to other parts of the body (localized). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may work better than radiation therapy alone in the treatment of patients with localized pancreatic cancer.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-30T13:50:49</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-141</PROTOCOL_NO>
    <TITLE>A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and In Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors with a KRAS G12c Mutation</TITLE>
    <NCT_ID>NCT04449874</NCT_ID>
    <SHORT_TITLE>Ph I GDC-6036 in Patients with Advanced Solid Tumors with a KRAS G12C Mutation</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
Men who are not surgically sterile must agree to remain abstinent or use contraception, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
Exclusion Criteria:

Active brain metastases.
Malabsorption or other condition that interferes with enteral absorption.
Clinically significant cardiovascular dysfunction or liver disease.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T20:21:08</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Genentech, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ETCTN-10144</PROTOCOL_NO>
    <TITLE>A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects</TITLE>
    <NCT_ID>NCT03375307</NCT_ID>
    <SHORT_TITLE>Ph II Olaparib in Patients w/ Metastatic/Advanced Urothelial Carcinoma w/ DNA-Repair Defects</SHORT_TITLE>
    <INVESTIGATOR_NAME>Arash Rezazadeh Kalebasty</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Patients must have a histologically confirmed diagnosis of urothelial carcinoma (cancer) of the urothelial tract/bladder cancer.
- Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparib.
- Patients must provide tumor sample for mutation analysis or be willing to undergo mandatory screening biopsy.

Exclusion Criteria: 
- Patients who have had prior treatment with olaparib or any other PARPi
- Patients who are receiving any other investigational agents. Patients may be on other clinical trials or treatment during screening to determine eligibility.
- Patients with known active hepatitis (i.e., Heptatitis B or C) due to risk of transmitting the infection through blood or other body fluids.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies how well olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-01-08T10:18:37</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ETCTN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-148</PROTOCOL_NO>
    <TITLE>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Tafasitamab plus Lenalidomide in Addition to Rituximab versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3A or R/R Marginal Zone Lymphoma (MZL)</TITLE>
    <NCT_ID>NCT04680052</NCT_ID>
    <SHORT_TITLE>Ph III Tafasitamab+Lenalidomide &amp; Rituximab in Pts w/ R/R Follicular Lymphoma or R/R MZ Lymphoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are ? 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are pregnant or breastfeeding.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-10-19T16:18:03</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Incyte Corporation</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-152</PROTOCOL_NO>
    <TITLE>Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers</TITLE>
    <NCT_ID>NCT03173950</NCT_ID>
    <SHORT_TITLE>Ph II Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers</SHORT_TITLE>
    <INVESTIGATOR_NAME>Daniela Bota</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

Inclusion Requirements
You can participate in this study if you
- have clinically confirmed recurrence of rare Central Nervous System (brain or spine) tumors
- are at least 18 years of age or older
- must be able to provide informed consent prior to study entry

Exclusion Requirements
You cannot participate in this study if you.
- are currently receiving other experimental drugs
- are pregnant or breastfeeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-19T09:56:19</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bristol-Myers Squibb</SPONSOR_NAME>
      <SPONSOR_NAME>NCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ECOG-EA2186</PROTOCOL_NO>
    <TITLE>A Randomized Phase II Study of Gemcitabine and NabPaclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Na√Øve Metastatic Pancreatic Cancer (GIANT)</TITLE>
    <NCT_ID>NCT04233866</NCT_ID>
    <SHORT_TITLE>PhII dFdC &amp; ABI-007 Compared w/5-FU, Leucovorin &amp; MM-398 in Older Pts w/Tx Na√Øve Met Pancreatic Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

- Patients must have newly diagnosed untreated biopsy-proven, metastatic pancreatic cancer. Previous surgery, adjuvant chemotherapy, and/or radiation therapy is allowed, provided radiation therapy is completed at least 2 weeks prior to registration and adjuvant therapy was administered more than 6 months prior to registration. Patients with the following histology are excluded: Acinar cell; Adenosquamous carcinoma.
- Patients must be at least 70 years of age or older.
- Patient must agree not to take any medications or substances that are strong inhibitors or inducers of CYP3A4 (important enzyme in the body, mainly found in the liver and in the intestine). Those who are randomized to liposomal irinotecan treatment arm should avoid drugs that are UGT1A1 (enzyme found in the liver) inhibitors.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to find out if two treatment combinations: Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan, is more effective at lengthening the lives of "vulnerable" patients over the age of 70 with metastatic pancreatic cancer. Currently, there is no known best practice for this type of patient. </DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-03-24T13:06:17</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-166</PROTOCOL_NO>
    <TITLE>Screening to Improve Survival in AL Amyloidosis</TITLE>
    <NCT_ID>NCT04615572</NCT_ID>
    <SHORT_TITLE>Screening to Improve Survival in AL Amyloidosis</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lisa Xingguang Lee</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>60 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Patients 60 years of age and older
- Diagnosed with &amp;#955; LC MGUS or &amp;#955; LC SMM
- dFLC greater than 23 mg/L and &amp;#954;::&amp;#955; free LC ratio below normal

If the patient has an eGFR less than 50 mL/min/1.73m2, the &amp;#954;::&amp;#955; free LC ratio is inconsequential. The patient only needs to meet the age, dFLC, and &amp;#955; LC MGUS or &amp;#955; LC SMM diagnosis criteria in this case 

Exclusion Criteria:

- Patients with &amp;#954; LC MGUS or &amp;#954; LC SMM
- Amyloid in the bone marrow or in other biopsies will not be included</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Screening</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-24T16:21:10</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Tufts Medical Center</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-169</PROTOCOL_NO>
    <TITLE>A Phase IB, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients with NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy
</TITLE>
    <NCT_ID>NCT04835805</NCT_ID>
    <SHORT_TITLE>PhIB HM95573 as SingleAgentCombo w/Cotellic or Cotellic+Tecentriq in Pts w/NRAS-Mutant Adv Melanoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>John P Fruehauf</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and over; Ability to comply with the study requirements; Life expectancy of more than or equal to 12 weeks; Confirmed diagnosis or medical records of Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma; Adequate organ functions defined by the laboratory test results; For women of child bearing potential - (refrain from heterosexual intercourse) or use a contraception; For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Signed Informed Consent Form ;Age = or &gt;  18 years; Ability to comply with the study protocol; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy &gt; or = 12 weeks; Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, previously treated with one or two lines of systemic anti-cancer therapy that included anti-PD-1 or anti PD-L1 therapy; Documentation of NRAS mutation-positive status in melanoma tumor tissue (archival or newly obtained), as determined by the local laboratory within 5 years prior to screening; Adequate hematologic and end-organ function, defined by the following laboratory test results; For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraception; For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to test the safety of an experimental drug called belvarafenib given alone (by itself) or in combination with cobimetinib or in combination with both cobimetinib and atezolizumab.  We want to find out what dose of belvarafenib plus cobimetinib should be used in people with melanoma (skin cancer).  In addition, we also want to find out what effects, good and/or bad, the study drug(s) have on you and your cancer, and to understand the way your body processes the study drug(s).</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-02-01T15:09:34</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Genentech, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-179</PROTOCOL_NO>
    <TITLE>A Phase I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients with Advanced Solid Tumors
</TITLE>
    <NCT_ID>NCT04528836</NCT_ID>
    <SHORT_TITLE>Ph I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 in Pts w/Adv Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Arash Rezazadeh Kalebasty</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Key Inclusion Criteria: 
- Male and non-pregnant females &gt;18 years old.
- Patients must have adequate organ function.
- Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures.

Key Exclusion Criteria: 
- Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection.
- Patients with clinically significant cardiac disease.
- Patients with a known additional malignancy that is progressing or requires active treatment.
- Patients on dialysis.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.</DESCRIPTION>
    <PHASE_DESC>Early Phase I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-01T11:39:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Navire Pharma Inc. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-186</PROTOCOL_NO>
    <TITLE>Assessment of Chimerism and Relapse Post Bone marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test (ACROBAT)</TITLE>
    <NCT_ID>NCT04635384</NCT_ID>
    <SHORT_TITLE>Assessment of Chimerism &amp; Relapse Post Bone Marrow/HCT Using AlloHeme Test (ACROBAT)</SHORT_TITLE>
    <INVESTIGATOR_NAME>Stefan Octavian Ciurea</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

-Male or female, aged 18 years or above.
-The patient must have one of the following diseases: Adult acute myeloid leukemia (AML), Acute lymphocytic leukemia
(ALL) or Myelodysplastic syndromes (MDS)
-Eligible for allogeneic hematopoietic stem cell transplant

Exclusion Criteria:
-Pregnancy</DETAILED_ELIGIBILITY>
    <DESCRIPTION>AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and donor peripheral blood sample will be collected to identify informative marker for routine chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone marrow samples are obtained and compared to the baseline sample profiles to calculate % chimerism of recipient cells in the blood and/or bone marrow samples. Cell selection from blood and bone marrow samples is applied to evaluate chimerism in specific cell subtypes that are relevant to AML and MDS diseases (CD3+ T lymphocytes, CD33+ Myeloid cells and CD15+ Granulocyte cell subtypes from blood and CD34+ hematopoietic stem cells from bone marrow).</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Diagnostic</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-04T10:14:56</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>CareDx, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ECOG-EA9181</PROTOCOL_NO>
    <TITLE>A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults</TITLE>
    <NCT_ID>NCT04530565</NCT_ID>
    <SHORT_TITLE>PhIII Steroids+Tyrosine KI Induction w/Chemo or Blinatumomab for New Diagnose BCR-ABL+ ALL in Adults</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are must be &amp;#8805; 18 and &amp;#8804; 75 years of age.



Exclusion Requirements.
You cannot participate in this study if you 
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-16T18:16:48</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-195</PROTOCOL_NO>
    <TITLE>Phase I/II Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-C-MET Bispecific Antibody, in Patients with Advanced NSCLC and Other Solid Tumors
</TITLE>
    <NCT_ID>NCT04868877</NCT_ID>
    <SHORT_TITLE>PhI/II Study of MCLA-129 in Pts w/Adv NSCLC &amp; Other Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced unresected disease that is incurable.
Patients with NSCLC or other solid tumors who have failed prior standard first-line treatment. Patients must have progressed on or be intolerant to therapies that are known to provide clinical benefit. There is no limit to the number of prior treatment regimens.
Availability of archival or a fresh tumor tissue sample.
Measurable disease as defined by RECIST version 1.1 by radiologic methods.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy &amp;#8805; 12 weeks, as per Investigator.

Exclusion Criteria:

Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy (&gt; 10 mg prednisone or equivalent) to control symptoms within 14 days of study entry.
Known leptomeningeal involvement.
Participation in another clinical study or treatment with any investigational drug within 4 weeks prior to study entry.
Prior treatment with a bispecific EGFR-c-MET antibody.
Systemic anticancer therapy or immunotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of study drug. For cytotoxic agents that have major delayed toxicity (e.g., mitomycin C, nitrosoureas), a washout period of 6 weeks is required.
Major surgery or radiotherapy within 3 weeks of the first dose of study drug.
Persistent grade &gt;1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy &amp;#8804; grade 2 NCI-CTCAE v5.0 and hypothyroidism &amp;#8804; grade 2 which is stable on hormone replacement are allowed.
History of hypersensitivity reaction or any toxicity attributed to human proteins or any of the excipients that warranted permanent cessation of these agents.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 as monotherapy in patients with NSCLC, or HNSCC or other solid tumors and who have progressed after receiving prior therapy for advanced/metastatic disease.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T20:10:55</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Merus N.V. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-196</PROTOCOL_NO>
    <TITLE>A Multi-Center, Open-Label, Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non Hodgkin Lymphoma of B-Cell Origin</TITLE>
    <NCT_ID>NCT04673617</NCT_ID>
    <SHORT_TITLE>PhI/II AB-101 Monotherapy &amp; AB-101 + Rituximab in Pts w/ Relapse/Refrac NHL of B-Cell Origin</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lauren C Pinter-Brown</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.

This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test the safety of AB-101 given alone or in combination with rituximab. The primary objective of Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with relapsed/refractory Non-Hodgkin lymphoma of B-cell origin.

Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of overall health and tumor response.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-02T14:29:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Artiva </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-20-198</PROTOCOL_NO>
    <TITLE>A Phase I, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies</TITLE>
    <NCT_ID>NCT04830137</NCT_ID>
    <SHORT_TITLE>PhI NX-2127, a BTK Degrader, in Adults w/ Relapse/Refract B-cell Malignancies</SHORT_TITLE>
    <INVESTIGATOR_NAME>Susan O'Brien</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are  &amp;#8805; 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-09T17:23:44</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Nurix Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S1925</PROTOCOL_NO>
    <TITLE>Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study</TITLE>
    <NCT_ID>NCT04269902</NCT_ID>
    <SHORT_TITLE>PhIII Early Intervene w/Venetoclax&amp;Obinutuzumab vsDelay w/Venetoclax&amp;Obinutuzumab in Pts w/CLL/SLL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Catherine Coombs</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study. 

Inclusion Criteria:

-Patients must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients must have been diagnosed within 12 months prior to registration.
-Patients must not have received or be currently receiving any prior CLL-directed therapy, including non-protocol-related therapy, anti-cancer immunotherapy, experimental therapy, or radiotherapy
-Patients must be &gt;= 18 years of age
-Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-Patients may not have had major surgery within 30 days prior registration or minor surgery within 7 days prior to registration. 
-Patients must not have known bleeding disorders (e.g., von Willebrand's disease or hemophilia).
-Patients must not be pregnant or nursing</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-06-11T11:24:38</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-03</PROTOCOL_NO>
    <TITLE>A Pilot Study of Immunotherapy Combined with Stereotactic Ablative Radiotherapy for Patients with Advanced or Metastatic Sarcoma
</TITLE>
    <NCT_ID>NCT05488366</NCT_ID>
    <SHORT_TITLE>A Pilot immunotherapy Combined w/Stereotactic Ablative Radiotherapy for Pts w/Adv or Met Sarcoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jeremy Harris</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
- are at least 18 years of age or older
- have been diagnosed with soft tissue sarcoma
- are not a candidate for surgery based on your doctor&amp;#8217;s assessment

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- are pregnant or nursing
- are receiving any other investigational agents</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this research study is to test if a combination of two treatments, immunotherapy and stereotactic ablative radiotherapy (SBRT), can delay tumor growth in patients with cancers that develop in their soft tissues (sarcomas).</DESCRIPTION>
    <PHASE_DESC>Early Phase I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-05-08T12:47:51</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES>
      <THERAPY_NAME>Radiotherapy</THERAPY_NAME>
    </THERAPY_NAMES>
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-04</PROTOCOL_NO>
    <TITLE>An Open-Label, Phase II Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas ("NAVAL-1")</TITLE>
    <NCT_ID>NCT05011058</NCT_ID>
    <SHORT_TITLE>Ph II Trial of Nanatinostat in Combo w/Valganciclovir in Subj w/EBV+ R/R Lymph ("NAVAL-1")</SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are  &amp;#8805; 18 years of age

Exclusion Requirements.
You cannot participate in this study if you are pregnant or breastfeeding.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-10-18T09:15:04</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Viracta Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ALLIANCE-A011801</PROTOCOL_NO>
    <TITLE>The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
</TITLE>
    <NCT_ID>NCT04457596</NCT_ID>
    <SHORT_TITLE>COMPASSHER2 RD Ph III Trial of T-DM1 &amp; Placebo Compared w/ T-DM1 &amp; Tucatinib</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) according to current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Central testing is not required
* Known hormone receptor (HR) status as defined by ASCO/CAP guidelines (based on pretreatment biopsy material). Hormone receptor positive status can be determined by either known positive estrogen receptor (ER) or known positive progesterone receptor (PR) status; hormone receptor negative status must be determined by both known negative ER and known negative PR
-Patients with clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively as defined above are eligible. (Note: Patients with T1a/bN0 tumors are not eligible at initial breast cancer diagnosis are not eligible)
-Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study. The presence of residual invasive disease in the breast is not mandatory for these patients
-Patients with weakly ER-positive (1-10%) breast cancer (based on the pretreatment core biopsy) are eligible even if they have node-negative disease per the surgical pathology report
-The residual disease tissue (breast and/or lymph nodes) is not required to be HER2-positive, as eligibility for NCI-2020-03770 (A011801) is based on a positive HER2 status at the time of the initial breast cancer diagnosis
* Note: The presence of micrometastases in lymph nodes after preoperative therapy counts as residual disease, whereas the presence of isolated tumor cells does not

Exclusion Criteria:
-No adjuvant treatment with any anti-cancer investigational drug within 28 days prior to registration
-Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative serum pregnancy test done =&lt; 7 days prior to registration is required
-Patients with known active and/or untreated hepatitis B or hepatitis C or chronic liver disease are ineligible. Patients with a diagnosis of hepatitis B or C that has been treated and cleared and normal liver function are eligible to participate in the study if the other eligibility parameters are met</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-07T17:32:51</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Alliance</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-09</PROTOCOL_NO>
    <TITLE>A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)</TITLE>
    <NCT_ID>NCT04960709</NCT_ID>
    <SHORT_TITLE>PhIIIDurvalumab w/Tremelimumab&amp;Enfortumab Vedotin orDurva w/EnfortumabVedotin forIneligCisplat MIBC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Arash Rezazadeh Kalebasty</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology;
- Medically fit for cystectomy and able to receive neoadjuvant therapy;
- Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC;
- Must have a life expectancy of at least 12 weeks at randomization.

Exclusion criteria:

- Evidence of lymph node (N2+) or metastatic TCC/UC disease at the time of screening.
- Active infection
- Uncontrolled intercurrent illness
- Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG])
- Current or prior use of immunosuppressive medication within 14 days before the first dose of IPs.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-03-28T14:24:07</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>AstraZeneca</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-18</PROTOCOL_NO>
    <TITLE>A Multicenter, OpenLabel Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy</TITLE>
    <NCT_ID>NCT04762069</NCT_ID>
    <SHORT_TITLE>Berubicin in Adult Pts w/ Recur GBM (WHO Grade IV) After Failure of Standard 1st Line Therapy</SHORT_TITLE>
    <INVESTIGATOR_NAME>Daniela Bota</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Inclusion Criteria:

- Confirmed Glioblastoma Multiforme (GBM) diagnosis based on local review of tumor tissue from the initial biopsy, surgery, re-resection, or a formal pathology report confirming GBM.
- No more than 1 prior line of cancer treatment (for example, surgery followed by radiation with concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of treatment).
- Patients with prior malignancies must be disease-free for &amp;#8805;5 years. However curatively
treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix,
breast, or bladder; or prostate cancer curatively treated at the time of screening is allowed.

Exclusion criteria:

- Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of screening), or any other acute viral, bacterial, or fungal infection (testing not required unless symptomatic or suspected disease).
- Patients with any other uncontrolled intercurrent medical conditions, including but not limited to diabetes mellitus or chronic obstructive pulmonary disease that have not been well controlled by medical management over the prior 3 months are ineligible unless approved by the sponsor.
- Prior treatment with bevacizumab and/or lomustine.</ELIGIBILITY>
    <DESCRIPTION>This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.

A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-08T15:34:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>CNS Pharmaceuticals</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-10</PROTOCOL_NO>
    <TITLE>A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors</TITLE>
    <NCT_ID>NCT04900818</NCT_ID>
    <SHORT_TITLE>PhI Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Patients with confirmed advanced or metastatic solid tumor whose disease has progressed beyond standard therapy or not a candidate for current treatment options. 
- Willingness and ability to consent for self to participate in study and the ability comply with scheduled visits, treatment plan, lab tests, and other study procedures.
- Male and female patients agreeable to use two forms of effective contraception methods while participating on study until 12 weeks after the last dose of study treatment. 

Exclusion Criteria:

- Patients are not eligible if they have had prior exposure to CLDN18.2-targeted therapy (therapy targeted to the CLDN 18.2 protein expressed in cancers). 
- Known active or chronic Hepatitis B, Hepatitis C, or HIV.
- Female patients in pregnancy, breastfeeding, or having a positive pregnancy test within 7 days prior to study treatment.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find out what effects, both good and/or bad, the study treatment has on you and your solid tumor.  The study drug, TJ033721, is investigational and has been tested in animals, but not yet in people. This means it has not been approved for commercial use by the United States Food and Drug Administration (FDA).</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-02-17T09:45:02</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>I-MAB Biopharma</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-12</PROTOCOL_NO>
    <TITLE>A Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
</TITLE>
    <NCT_ID>NCT04774952</NCT_ID>
    <SHORT_TITLE>A Phase I/IB Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Participants (male or female);18 years of age
-Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type

Exclusion Criteria:
-Known or suspected leptomeningeal or brain metastases or spinal cord compression
-Primary central nervous system (CNS) tumors</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T16:10:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Revolution Medicines</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-13</PROTOCOL_NO>
    <TITLE>Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression</TITLE>
    <NCT_ID>NCT04180371</NCT_ID>
    <SHORT_TITLE>Phase I/II Study of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling or analyses
- At least 18 years-of-age at the time of signature of the informed consent form
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Acceptable renal, hepatic, hematologic and coagulation functions
- Negative pregnancy test for women of childbearing potential
- Male participants with female partners of childbearing potential and female participants of childbearing potential are required to follow highly effective contraception
- All patients must have tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers. In the absence of available tumor tissue, patients must be willing to undergo a biopsy to provide fresh tumor samples
- Life expectancy greater than 12 weeks after the start of BT5528 treatment according to the Investigator's judgment.
- Must be willing and able to comply with the protocol and study procedures.

Additional inclusion criteria for Phase I (dose escalation phase, with BT5528 alone or in combination with nivolumab):

- Metastatic recurrent histologically confirmed malignant solid tumors historically known for high EphA2 tumor expression. Confirmation of EphA2 expression prior to enrollment is not required for participants with ovarian cancer and specific other individual tumor types.
- Exhausted all appropriate treatment options per local guidelines


Additional inclusion criteria for Phase II (dose expansion phase, with BT5528 alone):

- Participants with metastatic recurrent disease histologically confirmed to be non-small cell lung cancer, ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, head and neck (H&amp;N) cancer, urothelial cancer are eligible and must have failed or are ineligible for all appropriate treatment options per local guidelines and must have evidence of radiographic progression on the most recent line of therapy
- Patients with urothelial cancer who have previously received treatment with enfortumab vedotin (EV) are eligible to the study. Patients who received EV and showed disease progression within 6 months of treatment start are planned for less than 50% of total patients enrolled in the cohort

Exclusion Requirements
You cannot participate in this study if you
- Chemotherapy treatments within 14 days prior to first dose of study treatment, other anticancer treatments, treatment within 28 days or 5 half-lives, whichever is the shorter
- Experimental treatments within 4 weeks of first dose of BT5528
- Prior toxicities must have resolved to Grade 1 per Common Terminology Criteria for Adverse - - Events (CTCAE) v 5.0 (except alopecia which can be Grade 2)
- Current treatment with strong inhibitors or inducers of CYP3A4 or strong inhibitors of P-gp
Known sensitivity to any of the ingredients of the investigational product or monomethyl auristatin E (MMAE)
- Any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the investigator including but not limited to specific cardiovascular criteria
- Major surgery (excluding placement of vascular access) within 4 weeks of first dose of BT5528 study </DETAILED_ELIGIBILITY>
    <DESCRIPTION>Brief Summary:
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:

- Find the recommended dose of BT5528 that can be given safely to participants alone and in combination with nivolumab
- Learn more about the side effects of BT5528
- Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
- Learn more about BT5528 therapy alone and in combination with nivolumab.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T14:22:13</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bicycle Tx Limited</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-16</PROTOCOL_NO>
    <TITLE>Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL</TITLE>
    <NCT_ID>NCT04852822</NCT_ID>
    <SHORT_TITLE>Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Susan O'Brien</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Requirements
You can participate in this study if you 
&amp;#8226;	Are 18 years of age or older
&amp;#8226;	Have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 
&amp;#8226;	Are willing and able to participate in all required evaluations and procedures in this study 


Exclusion Requirements 
You cannot participate in this study if you 
&amp;#8226;	Have prior SARS-CoV-2/COVID19 infection 
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this research study is to find out how your blood immune markers change before and after a vaccination. We will use samples and data to better understand how your body&amp;#8217;s immune system reacts to the COVID-19 vaccine.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Other</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-06-11T11:30:52</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>University of Washington</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-17</PROTOCOL_NO>
    <TITLE>A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk Myelodysplastic Syndrome</TITLE>
    <NCT_ID>NCT04797780</NCT_ID>
    <SHORT_TITLE>PhIII SY-1425 + Azacitidine vsPlacebo +Azacitidine in New Diagnosed RARA+ Adult Pts w/HigherRisk MS</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult, Older Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Key Inclusion Criteria:
1. Participants must be at least 18 years old at the time of signing of an informed consent.
2. Participants must be newly diagnosed with Higher Risk-MDS 

Key Exclusion Criteria:
1. Participants are suitable for and agree to undergo allogeneic HSCT at the time of Screening.
2. Participants who received prior treatment for MDS with any hypomethylating agent, chemotherapy or allogeneic HSCT.
3. Patients have an active, life-threatening, or clinically-significant, uncontrolled systemic infection requiring hospitalization.
4. Patients have a known malabsorption syndrome or other condition that may impair absorption of study medication (e.g., gastrectomy).
5. Pregnant females, breastfeeding females, and males not willing to comply with contraceptive requirements or females of childbearing potential not willing to comply with contraceptive requirements.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-06T23:02:56</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Syros</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-19</PROTOCOL_NO>
    <TITLE>A Phase I/II, Open-Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NonHodgkin s Lymphoma or Chronic Lymphocytic Leukemia</TITLE>
    <NCT_ID>NCT05360238</NCT_ID>
    <SHORT_TITLE>PhI/II MB-106 in Pts w/ Relapse or Refra CD20+ B-Cell Non-Hodgkin s Lymph or CLL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Susan O'Brien</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-11T12:26:10</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Mustang</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ECOG-EA6141</PROTOCOL_NO>
    <TITLE>Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma</TITLE>
    <NCT_ID>NCT02339571</NCT_ID>
    <SHORT_TITLE>PhII/IIINivolumab+Ipilimumab+Sargramostim vsNivolumab+Ipilimumab inPts w/UnresecStg IIIorIV Melanoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult, Older Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Patients must have known BRAF mutational status of tumor; wild-type (WT) or mutated, prior to randomization
-Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for at least one week prior to the start of the research study, and continuing for 5 months for women of childbearing potential and 7 months for sexually active males after the last dose of the study drugs
-Patients must have unresectable stage III or stage IV melanoma; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive
-Adequate organ functions based on lab values
-Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible

Exclusion Criteria:
-Women must not be pregnant or breast-feeding due to use of cytotoxic immunotherapy and risk of teratogenic side effects; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting
-Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
-Patients must not have any serious or unstable pre-existing medical conditions
-Patients with human immunodeficiency virus (HIV) infection are ineligible;
-Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible; patients with cleared HBV and HCV (0 viral load) infection will be allowed
-Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis); other CNS autoimmune disease (e.g., multiple sclerosis)
-Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
-Patients must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T09:33:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-27</PROTOCOL_NO>
    <TITLE>A Phase I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer</TITLE>
    <NCT_ID>NCT04862780</NCT_ID>
    <SHORT_TITLE>Ph I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant NSCLC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>&amp;#8805;18 years of age at the time of signing the informed consent.
Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation.
Previously received at least 1 prior EGFR-targeted TKI. For patients enrolled to expansion Group 2, prior treatment must include an approved EGFR-targeted TKI with activity against the T790M mutation, such as osimertinib.
EGFR mutation profile determined locally via a Sponsor-approved testing methodology, using either tumor tissue (ideally from a progressing lesion) and/or ctDNA in plasma. It is preferable that samples used for analysis be obtained during or after disease progression on the last EGFR-targeted TKI received.

Dose escalation: At each dose level, slots may be reserved for patients with the mutations of interest.
Expansion Groups: Patients must have NSCLC harboring EGFR T790M and C797S mutation (Group 1); EGFR T790M but not C797S (Group 2); or EGFR C797S but not T790M (Group 3).
Pretreatment tumor sample (either an archival sample or a sample obtained by pretreatment biopsy) submitted for central analysis. It is preferable that pretreatment tumor samples be obtained from a progression lesion, during or after disease progression on the last EGFR-targeted TKI received.

Patients without archival tissue available, where biopsy is not considered safe and/or medically feasible, may be discussed with the study medical monitor and may be approved for enrollment on a case-by-case basis.

Phase 2 Expansion Groups: Patient has at least 1 measurable target lesion evaluable by RECIST 1.1 as assessed by the investigator.
Eastern Cooperative Oncology Group (ECOG) performance status is 0-2.
Agrees to use contraception consistent with local regulations</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-06-08T15:09:31</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Blueprint Medicines</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-35</PROTOCOL_NO>
    <TITLE>Outcomes of Cutaneous Melanoma Patients Clinically Tested DecisionDx - Melanoma (CONNECTION)</TITLE>
    <NCT_ID />
    <SHORT_TITLE>Outcomes of Cutaneous Melanoma Patients Clinically Tested DecisionDx -Melanoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>James Jakowatz</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY />
    <DETAILED_ELIGIBILITY>1. Patient diagnosed with biopsy confirmed Stage I, Stage II or Stage III (at time of diagnosis) cutaneous melanoma (CM).
2. Patient is greater than or equal to 18 years of age at the time of diagnosis.
3. Patient who received successful DecisionDx¬Æ-Melanoma test results whose test was ordered between January 1, 2013 and December 31, 2017.
** Patient who has more than one invasive CM lesion tested, must be enrolled only once, using the highest-risk lesion (per DecisionDx¬Æ-Melanoma) as the lesion under study.
Patients who have not experienced a metastatic event must meet the additional following criteria:
4. Patient must have a minimum of 3 years documented clinical follow up demonstrating they have not experienced a metastatic event (this includes regional and distant metastatic events).
Patients who have experienced a metastatic event must meet the following additional criteria:
5. Patient must have documentation of melanoma metastasis and/or melanoma-specific death but is not required to have a full three years documented clinical follow up.
Exclusion
1. No exclusions except not meeting inclusion criteria above.</DETAILED_ELIGIBILITY>
    <DESCRIPTION />
    <PHASE_DESC />
    <TREATMENT_TYPE_DESC>Diagnostic</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-03T10:21:03</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Castle Biosciences Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S1914</PROTOCOL_NO>
    <TITLE>S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC</TITLE>
    <NCT_ID>NCT04214262</NCT_ID>
    <SHORT_TITLE>PhIII Atezolizumab Plus SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jeremy Harris</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0). Patient may have T3 disease with the exclusion of multifocal tumors and pericardial involvement
Disease must have one or more of the following high-risk features:

Tumor diameter &gt;= 2 cm as assessed by diagnostic computed tomography (CT)
Tumor standard uptake value (SUV) max &gt;= 6.2 as assessed by fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/CT
Moderately differentiated, poorly differentiated, or undifferentiated histology
Patient must have undergone diagnostic chest CT with contrast (unless medically contraindicated) within 42 days prior to randomization. PET-CT may be used if the CT portion is of identical diagnostic quality to a stand-alone CT. All disease must be assessed within 42 days prior to randomization
Patient must have undergone FDG PET/CT of chest within 90 days prior to randomization
Patient must not have evidence of hilar or mediastinal nodal involvement. Any patient with radiographically suspicious hilar or mediastinal nodes (including features such as non-calcified nodes with a short axis diameter &gt; 1 cm, abnormal morphology, and/or elevated FDG avidity) must undergo cytologic sampling of suspicious nodes to rule out involvement prior to randomization. Mediastinal nodal sampling for other patients is optional
Patient must have undergone history and physical examination within 28 days prior to randomization
Patient must be medically or surgically inoperable as documented by a board certified thoracic surgeon or multi-disciplinary tumor board consensus OR patient's unwillingness to undergo surgical resection must be clearly documented
Patient must not have received any prior treatment for the current NSCLC diagnosis
Patient must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment
Patient must not have received treatment with systemic immunostimulatory or immunosuppressive agents, including corticosteroids, within 14 days prior to randomization
Patient must be &gt;= 18 years old
Patient must have Zubrod performance status of 0-2
Patient must have adequate liver function defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3 x institutional upper level of normal (IULN) within 28 days prior to randomization
Patient must have adequate renal function defined as calculated creatinine clearance &gt;= 30 mL/min using the following formula. The serum creatinine value used in the calculation must have been collected within 28 days prior to randomization
Patient must have absolute neutrophil count (ANC), platelets, and hemoglobin measured within 28 days prior to randomization. The purpose of these tests is to collect baseline values to compare with on-treatment values
Patient must have thyroid-stimulating hormone (TSH) measured within 28 days prior to randomization. The purpose of this test is to collect baseline values to compare with on-treatment values
Patient must not have significant cardiovascular disease (New York Heart Association [NYHA] class II or greater)
Patient must not have myocardial infarction within 90 days prior to randomization
Patient must not have unstable arrhythmias or unstable angina
Patient must not have known left ventricular ejection fraction &lt; 40% within 28 days prior to randomization</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-06T22:37:35</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-38</PROTOCOL_NO>
    <TITLE>An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy</TITLE>
    <NCT_ID>NCT04130542</NCT_ID>
    <SHORT_TITLE>Ph I LVGN6051 as Single Agent &amp; in Combo w/ Keytruda (Pembrolizumab) in Adv or Met Malignancy</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult, Older Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Males or females aged &amp;#8805; 18 years.
- Ability to understand and willingness to sign a written informed consent document.
- Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.

Exclusion Criteria: 
- Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment.
- Previous radiotherapy within 14 days of the first dose of study treatment.
- Has received a live-virus vaccine within 30 days.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137.

This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab/MK-3475) in the treatment of advanced or metastatic malignancy.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-28T16:25:38</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Lyvgen BioPharma Holdings Limited</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-39</PROTOCOL_NO>
    <TITLE>An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer with a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab</TITLE>
    <NCT_ID>NCT04701476</NCT_ID>
    <SHORT_TITLE>PhII Tx of Liver Met Colorectal Ca &amp; NSCLC w/ a Combo of TATE &amp; Pembrolizumab</SHORT_TITLE>
    <INVESTIGATOR_NAME>Nadine Abi-Jaoudeh</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
mCRC progressed on at least two lines of standard chemotherapy; or
NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
Measurable disease
ECOG 0-1
At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
Adequate organ function

Exclusion Criteria:
Prior organ transplantation
Liver metastasis more than 50%
Oxygen saturation less than 92% in room air
Prior autoimmune disorder
CNS metastasis
Major GI bleeding in the last 2 months</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T09:42:21</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Teclison Limited</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-40</PROTOCOL_NO>
    <TITLE>A Phase I/II, First-in-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications  </TITLE>
    <NCT_ID>NCT04423029</NCT_ID>
    <SHORT_TITLE>PhI/IIDF6002 as Mono &amp;Combo w/Nivolumab in Pts w/Local Adv or Met Solid Tumors &amp; Expan in Select Ind</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Male or female patients aged 18 years and over</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>General Inclusion and Exclusion Criteria 
- Male or Female patients ages 18 years and over
-Histologically or cytologically proven locally advanced or metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate.
-Clinical or radiological evidence of disease
-Adequate hematological, hepatic and renal function
-Effective contraception for women of child-bearing potential as defined by World Health Organization guidelines for 1 "highly effective" method or 2 "effective" methods
Additional Phase 1 Monotherapy and Phase 1b Combination With Nivolumab Expansion Inclusion Criteria:
-Has one of the following tumor types: melanoma, non-small cell lung cancer, or triple negative breast cancer
-Agrees to undergo a pre-treatment biopsy and another biopsy while on treatment
Expansion Inclusion Criteria specific to Melanoma:
-Histologically confirmed, unresectable Stage III or Stage IV melanoma, as specified in the American Joint Committee on Cancer staging system.
-Participants with ocular or uveal melanoma are ineligible.
-Must have documented progressive or recurrent disease on or after discontinuation of anti-PD-(L)1 therapy
Additional Inclusion Criteria for Phase 2 (Advanced Melanoma Patients)
-Participants who received anti-PD-(L)1 in the advanced/metastatic setting, must have documented progressive or recurrent disease on or within 3 months of discontinuation of anti-PD-(L)1 therapy
-Participants who received anti-PD-(L)1 in the adjuvant setting must have documented progressive or recurrent disease on or within 6 months of discontinuation of anti-PD-(L)1 therapy
-Disease progression was confirmed at least 4 weeks after the initial diagnosis of disease progression while receiving an anti PD-1 antibody.
-Participants with ocular or uveal melanoma are ineligible.
-Confirmation of radiographic progression on prior anti-PD-(L)1 therapy is required
Exclusion Criteria for All Patients (All Phases)
-Prior treatment with rhIL2 or any recombinant long acting drug containing an IL2 moiety.
-Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment.
-Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ.
-Rapidly progressive disease.
-Any Grade 2 and higher neurological or pulmonary toxicity during a treatment with an anti-PD-1 or PD-L1 agent administered as a monotherapy.
-Active or history of central nervous system (CNS) metastases.
-Receipt of any organ transplantation, autologous or allogeneic stem-cell transplantation.
-Significant acute or chronic infections, or active or latent hepatitis B or active hepatitis C.
-Preexisting autoimmune disease needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, clinically relevant immunodeficiencies, or fever within 7 days of Day 1.
-Known severe hypersensitivity reactions to monoclonal antibodies and any history of anaphylaxis, or uncontrolled asthma
-Serious cardiac illness or medical conditions.
History of life-threatening toxicity related to prior immune therapy except those that are unlikely to re-occur with standard countermeasures.
Contacts and Locations</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with nivolumab.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-05-13T16:44:00</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bristol-Myers Squibb</SPONSOR_NAME>
      <SPONSOR_NAME>Dragonfly Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-47</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of the Highly Selective ROS1 Inhibitor NUV=520 in Patients with Advanced NSCLC and Other Solid Tumors</TITLE>
    <NCT_ID>NCT05118789</NCT_ID>
    <SHORT_TITLE>Ph I/II Highly Selective ROS1 Inhibitor NUV=520 in Pts w/ Adv NSCLC &amp; Other Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Age &amp;#8805;18 years (Cohort 2e only: Age &amp;#8805;12 years and weighing&gt;40 kg).
Phase 1:

Histologically or cytologically confirmed metastatic solid tumor with documented ROS1 rearrangement.
Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed metastatic NSCLC with ROS1 rearrangement.
Cohort 2e: Histologically or cytologically confirmed metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.
Prior anticancer treatment (except cohort 2a).
Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.
Adequate baseline organ function and bone marrow reserve.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors.

Phase 1 will determine the RP2D and/or maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors.

Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T16:01:21</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Nuvalent, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-53</PROTOCOL_NO>
    <TITLE>A Phase Ia/Ib Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors </TITLE>
    <NCT_ID>NCT04956640</NCT_ID>
    <SHORT_TITLE>A Phase Ia/Ib Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors </SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).
Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Have adequate organ function.
Have discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs).
Must be able to swallow capsule/tablet.
Agree and adhere to contraceptive use, if applicable.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability, and preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors.

This study will be conducted in 2 parts, Part 1a is a dose escalation and Part 1b is a dose expansion. Part 1a will establish a recommended Phase 2 dose. Part 1b will have multiple arms of either monotherapy or in combination with other drugs.

KRAS G12C mutations will be identified through standard of care testing.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-01-05T15:56:19</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Loxo Oncology, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-57</PROTOCOL_NO>
    <TITLE>A Phase Ib/II, Two-Part, Open-Label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination with ALX148 in Advanced HER2-Expressing Cancer</TITLE>
    <NCT_ID>NCT05027139</NCT_ID>
    <SHORT_TITLE>Ph Ib/II Zanidatamab in Combo w/ALX148 in Adv HER2-Expressing Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Locally advanced (inoperable) and/or metastatic HER2-expressing cancer based on local or central laboratory test results
- Progression after or during the most recent systemic regimen of treatment for advanced cancer.
- The subject is willing and able to comply with study procedures.

Eligibility Criteria
- Previous allogeneic stem cell transplant.
- Had major surgery within 4 weeks of the first dose of zanidatamab/ALX148.
- Poorly-controlled seizures.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-14T08:41:46</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Zymeworks</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-62</PROTOCOL_NO>
    <TITLE>Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
</TITLE>
    <NCT_ID>NCT03744468</NCT_ID>
    <SHORT_TITLE>PhI/II BGB-A425 in Combo w/ Tislelizumab in Pts w/ Adv Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Criteria
Key Inclusion Criteria:

Phase 1: Patients with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who have previously received standard systemic therapy or for which treatment is not available, not tolerated or refused.
Has Eastern Cooperative Oncology Group (ECOG) Performance Status &amp;#8804;1.
Phase 2: Patients with one of the following histologically or cytologically confirmed solid tumors:
Cohort 1 (HNSCC, PD-L1 positive):

Recurrent/metastatic head and neck squamous cell cancer of the oral cavity, oropharynx, hypopharynx, and/or larynx whose tumor is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy

Cohort 2 (NSCLC, PD-L1 positive):

Locally recurrent Stage IIIB, stage IIIC or Stage IV squamous or non-squamous non-small cell lung cancer

Cohort 3 (RCC):

Locally advanced unresectable or metastatic and histologically confirmed renal cell carcinoma with a clear cell histology

Key Exclusion Criteria:

Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Active autoimmune diseases or history of autoimmune diseases that may relapse.
With infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy &amp;#8804; 14 days prior to the first dose of study drug(s), or a requirement for chronic prophylactic treatment with antibiotics.
Concurrent participation in another therapeutic clinical trial. 6. Received prior therapies targeting TIM-3.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-06-30T15:18:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>BeiGene, Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-77</PROTOCOL_NO>
    <TITLE>An Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinectics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)</TITLE>
    <NCT_ID>NCT04947319</NCT_ID>
    <SHORT_TITLE>PhII Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma </SHORT_TITLE>
    <INVESTIGATOR_NAME>Daniela Bota</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Pathologically diagnosed with Primary Central Nervous System Lymphoma
- Life expectancy of at least 3 months (part A) or at least 6 months (part B)
- Adequate bone marrow, renal, and hepatic function as described by the study protocol

Exclusion Criteria:
- Patient who is intolerant of contrast-enhanced MRI due to allergic reactions to contrast agents
- Patient with systemic presence of lymphoma
- Prior radiotherapy within 14 days before starting tirabrutinib (study drug) treatment</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment na√Øve PCNSL (Part B)</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-06-17T16:13:53</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ONO Pharmaceutical Co., Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-98</PROTOCOL_NO>
    <TITLE>Phase III Randomized, Controlled Study of Blinatumomab Alternating with Low-Intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia with Safety Run-In </TITLE>
    <NCT_ID>NCT04994717</NCT_ID>
    <SHORT_TITLE>PhIIIBlinatumomab Alter w/LI Chemo vsSOC for OldAdults w/ND Phil(-) BCell Precur ALL w/SafeRunIn</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female ages &amp;#8805; 55 years at the time of informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-07T20:35:12</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-99</PROTOCOL_NO>
    <TITLE>An Open-Label, Multi-Center, Non Randomized Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma </TITLE>
    <NCT_ID>NCT05079282</NCT_ID>
    <SHORT_TITLE>PhI of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lauren C Pinter-Brown</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-04-12T16:36:57</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ONO Pharmaceutical Co., Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S2007</PROTOCOL_NO>
    <TITLE>A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases</TITLE>
    <NCT_ID>NCT04647916</NCT_ID>
    <SHORT_TITLE>Ph II of Sacituzumab Govitecan for Patients w/ HER2-Negative Breast Ca &amp; Brain Met</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Participants must have histologically confirmed HER2-negative (per 2018 American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] joint guideline) invasive breast cancer that has metastasized to the brain. NOTE: Pathology report must confirm HER2-negative invasive breast cancer. Brain metastases must be confirmed by radiology report
- Participants must have an magnetic resonance imaging (MRI) of the brain within 28 days prior to registration and must have central nervous system metastases with at least one measurable brain metastasis &gt;= 1.0 cm in size (per RANO-BM) that has not been irradiated, or has progressed despite prior radiation therapy (in the opinion of the treating physician). In the rare case that a previously irradiated brain metastasis is the sole target lesion and if there is concern about possible radiation necrosis, patient is eligible only if there is clear progression in the previously radiated lesion. Computed tomography (CT) of the head cannot substitute for brain MRI. All central nervous system (CNS) disease must be assessed and documented on the S2007 Brain Metastases Baseline Tumor Assessment Form

Exclusion Criteria:
-Participants must not have had more than 2 seizures within 28 days prior to registration
-Participants must not have received systemic therapy (including small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (e.g., tamoxifen) within 7 days prior to registration
-Participants must not have received anti-cancer biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to registration</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-08-06T17:05:50</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-105</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of REGN5093-M114 (METXMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer</TITLE>
    <NCT_ID>NCT04982224</NCT_ID>
    <SHORT_TITLE>PhI/II REGN5093-M114 in Patients with MET Overexpressing Advanced Cancer</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit as defined in the protocol
- Willing to provide tumor tissue from newly obtained biopsy from tumor site. Newly obtained biopsies at tissue screening are required. An archival sample can be accepted only after discussion with the medical monitor and if the sample is not more than 6 months old and obtained after completion of the last therapy. The enrollment of patients will be based on an immunohistochemistry (IHC)-based assay using freshly obtained tumor biopsies or an archival biopsy as described above. Only patients with MET overexpressing tumors by central IHC analysis will be enrolled. For expansion cohorts only: tumor site for biopsy must not have been irradiated previously and must not be the only measurable lesion.
- Tumor must overexpress MET protein as defined in the protocol by central IHC analysis
- For expansion only: At least one lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and bone marrow function as defined in the protocol

Exclusion Requirements
You cannot participate in this study if you
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy
- Has not yet recovered (ie, grade &amp;#8804;1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol
- Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered from adverse events as defined in the protocol
- Another malignancy that is progressing or requires active treatment except as noted in the protocol
- Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Encephalitis, meningitis, organic brain disease (eg Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy
- Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency as defined in the protocol</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Brief Summary:
The primary objective of the dose escalation (phase 1) part of the study is:

To assess the safety, tolerability and pharmacokinetics (PK) of the antibody drug conjugate (ADC) REGN5093-M114 in order to determine a maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) of REGN5093-M114 in patients with mesenchymal epithelial transition factor (MET) overexpressing non-small cell lung cancer (NSCLC).

The primary objective of the dose expansion (phase 2) part of the study is:

To assess preliminary anti-tumor activity of REGN5093-M114 in MET-overexpressed NSCLC as measured by the objective response rate (ORR)

The secondary objective of the dose escalation (phase 1) part of the study is:

To assess preliminary anti-tumor activity of REGN5093-M114 as measured by the ORR

The secondary objective of the dose expansion (phase 2) part of the study is:

To assess the safety, tolerability profile, and PK of REGN5093-M114 ADC and total antibody in each expansion cohort

The secondary objectives of both phases of the study are:

To evaluate other measures of preliminary anti-tumor activity
To assess immunogenicity to REGN5093-M114</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T14:09:05</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Regeneron Pharmaceuticals, Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-108</PROTOCOL_NO>
    <TITLE>A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors</TITLE>
    <NCT_ID>NCT04919811</NCT_ID>
    <SHORT_TITLE>Ph II Taletrectinib in Pts w/ Adv or Met ROS1 Positive NSCLC &amp; Other Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 years and older </ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibilities:
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC or other solid tumors.
- Evidence of ROS1 fusion in tumor tissue determined by molecular assays as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified or locally equivalent laboratories.
- Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme inducing anti-epileptic drugs (non-EIAEDs). If corticosteroid treatment is required, it should be on stable or decreasing dose of &amp;#8804;10 mg prednisone or equivalent. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment at least 14 days before enrollment and be clinically stable.
- The patient is either ROS1 TKI treatment na√Øve, or treated with prior ROS1 TKI(s).
Exclusion:
- Investigational agent or anticancer therapy within 2 weeks (or 5 half-lives of the compound, whichever is longer) prior to study enrollment. In addition, no concurrent anticancer therapy is permitted.
- Previously treated with immuno-oncology (IO) including immune checkpoint inhibitors within 12 weeks before enrollment.
- Major surgery within 4 weeks prior to enrollment.
- Radiation therapy with a limited field for palliation within 1 week of the first dose of study treatment.
- Toxicities due to prior therapy are unresolved to &amp;#8804; CTCAE 5.0 Grade 1 except for AEs not constituting a safety risk to the patient based on the judgment of investigators.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a global Phase 2, multicenter, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.

119 patients will be enrolled and divided into 4 cohorts, depending on past history of ROS1 TKI treatment.

Taletrectinib will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator.

The tumor response evaluation will be conducted on a regular basis until progression of disease. Long-term survival follow up will be conducted as well.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-06-01T13:12:58</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>AnHeart Therapeutics</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-110</PROTOCOL_NO>
    <TITLE>Phase Ib/II Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)</TITLE>
    <NCT_ID>NCT05039177</NCT_ID>
    <SHORT_TITLE>Ph Ib/II Agents Targeting Mitogen-Activated Protein Kinase Pathway in Pts w/Adv Gastro Malignancies </SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
1. Have histologically or cytologically confirmed metastatic colorectal cancer (CRC) harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) based on an analytically validated assay performed on tumor tissue in a certified testing laboratory
2. Willing to comply with all protocol-required visits, assessments, and procedures
3. Able to swallow oral medication

Exclusion Criteria:
1. Symptomatic brain metastasis or leptomeningeal disease.
2. Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment.
3. Pregnant or breastfeeding women
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is being done to test ERAS-007 in combination with other drugs for the treatment of advanced or metastatic colorectal cancer.  The study is divided into sub-studies based on mutation status and number of prior therapies.  You are being asked to take part in this portion of the research study because you have been diagnosed with a type of advanced or metastatic colorectal cancer with a specific change (or mutation) in the BRAF gene (BRAF V600E).  This change leads to the uncontrolled growth and spread of the affected colon cells into colon cancer.  ERAS-007 in combination with other therapies is designed to target these mutations.  ERAS-007 is an investigational drug that has shown anti-cancer activity in animals and humans by blocking a cell pathway that contributes to cancer formation and progression.  Investigational means that the drug has not been approved by health authorities, such as the United States Food and Drug Administration (US FDA), for the treatment of people with your medical condition.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-03-23T10:29:40</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Erasca</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-124</PROTOCOL_NO>
    <TITLE>Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers</TITLE>
    <NCT_ID>NCT05497531</NCT_ID>
    <SHORT_TITLE>Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hep &amp; Pancreatic Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Nadine Abi-Jaoudeh</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of
study criteria to help you better understand how your eligibility in the study will be determined; your study
team will go through the study eligibility criteria with you to verify if you qualify for participation in this
study.

Inclusion Requirements
You can participate in this study if you
- Are 18 years of age or older
- Have or are undergoing work-up for hepatobiliary and/or pancreatic cancer
- Are scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion

Exclusion Requirements
You cannot participate in this study if you
- Have a gross body weight over 375 pounds
- Have moderate to severe ascites (abdominal swelling caused by accumulation of fluid)
and unable to undergo trans-jugular biopsy or sufficient drainage
- Cannot have a peripheral blood draw for ctDNA</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a, prospective single center pilot study to investigate whether ctDNA detection can be improved by sampling the cancer draining vein vs. a peripheral vein (current practice). As a secondary endpoint, both ctDNA results will be compared with percutaneous biopsy (standard of care).</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Diagnostic</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-07T11:29:17</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-144</PROTOCOL_NO>
    <TITLE>A Phase I, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignances with Isocitrate Dehydrogenase (IDH) Mutations</TITLE>
    <NCT_ID>NCT04764474</NCT_ID>
    <SHORT_TITLE>Ph I HMPL-306 in Adv Hematological Malignances w/ Isocitrate Dehydrogenase (IDH) Mutations</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>	AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-07T13:10:56</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Hutchison MediPharma Limited</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-BR007</PROTOCOL_NO>
    <TITLE>A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer</TITLE>
    <NCT_ID>NCT04852887</NCT_ID>
    <SHORT_TITLE>PhIIIDeEscalate of BreastRad for Tx of StgI, Horm Sensitive HER2- Onco Recur Score &gt;/= to 18BreastCa</SHORT_TITLE>
    <INVESTIGATOR_NAME>Rita Mehta</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults, Older Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.
- The patient must be &gt;= 50 years and &lt; 70 years of age.
- The patient must have an ECOG performance status of 0 or 1.
- The trial is open to female and male patients.
- The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection.)
- The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.

Exclusion Criteria: 
- Patient had a mastectomy.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
- Use of any investigational product within 30 days prior to study entry.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-02-24T20:31:05</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-146</PROTOCOL_NO>
    <TITLE>An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors</TITLE>
    <NCT_ID>NCT04843709</NCT_ID>
    <SHORT_TITLE>Ph I/II MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria: 
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- A negative serum pregnancy test (if female and aged between 18-55 years old). Women who are pregnant or breast feeding are not to be included.
- Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types&amp;#8211; Part A and Part B 

Exclusion Criteria: 
- Concurrent malignancy within 5 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer, thyroid cancer not requiring treatment, ductal carcinoma in situ of the breast, or &lt;T1 urothelial carcinoma
- Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
- Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-03T17:27:51</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Shanghai Miracogen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-156</PROTOCOL_NO>
    <TITLE>A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZDO171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors</TITLE>
    <NCT_ID>NCT04999969</NCT_ID>
    <SHORT_TITLE>PhII AZDO171 in Combo w/Durvalumab &amp;Chemo in Pts w/Local Adv orMet Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years to 130 Years </ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
You must have an Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment
You must have a Gustave Roussy Immune Score of 0 or 1
You must be diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma
You must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1
You must consent to providing sufficient archival specimen taken during metastatic stage or fresh tumour specimens for tumoural CD8+ T cell testing for enrolment
You must have normal organ and bone marrow function measured within 28 days prior to first dose of study intervention
Your body weight must be greater than or equal to 35 kg</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-08-25T08:26:39</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>AstraZeneca</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-161</PROTOCOL_NO>
    <TITLE>A Phase I/II Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors</TITLE>
    <NCT_ID>NCT03504488</NCT_ID>
    <SHORT_TITLE>Ph I/II Study of Ozuriftamab Vedotin (BA3021) Alone &amp; in Combo w/Nivolumab in Pts w/Adv Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
-For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
-Life expectancy of at least three months.

Exclusion Criteria:
-Patients must not have clinically significant cardiac disease. 
-Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
-Patients must not be women who are pregnant or breast feeding.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors.

This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-21T14:14:54</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bioatla</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-LU007</PROTOCOL_NO>
    <TITLE>Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial</TITLE>
    <NCT_ID>NCT04402788</NCT_ID>
    <SHORT_TITLE>Ph II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jeremy Harris</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria
- Pathologically proven diagnosis of extensive stage small cell lung cancer
- Patients with bone metastases are eligible 
- For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to registration

Exclusion Criteria
-Metastatic disease invading the liver (&gt;3 metastases), heart or &gt;10 metastatic sites detectable after induction systemic therapy
-Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 5 years prior to randomization
-History of autoimmune disease
-Severe, active co-morbidity 
-Pregnancy or women who are breastfeeding and unwilling to discontinue.
-History of allogeneic organ transplant.
-Patients who have had immunotherapy-induced  pneumonitis.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is being done to know if we extend the time without extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer (an immunotherapy drug called atezolizumab). As well to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for extensive stage small cell lung cancer.</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-24T15:28:00</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES>
      <THERAPY_NAME>Radiotherapy</THERAPY_NAME>
    </THERAPY_NAMES>
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ECOG-EA2176</PROTOCOL_NO>
    <TITLE>A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na√Øve Metastatic Anal Cancer Patients</TITLE>
    <NCT_ID>NCT04444921</NCT_ID>
    <SHORT_TITLE>Ph III Immune Checkpoint Inhibition w/Chemo in Tx-Na√Øve Met Anal Ca Pts</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

You are eligible to participate if:

- You have inoperable, recurrent, or metastatic disease.
- You have confirmed anal cancer (includes basaloid and cloacogenic lesions).
- You are a woman and currently not pregnant or breast-feeding.
- You have not had prior immunotherapy. 
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is being done to answer the following question: Will adding an immune checkpoint inhibitor to the usual combination of chemotherapy drugs help prevent your cancer from getting worse?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your anal canal cancer. The usual approach is defined as care most people get for na√Øve metastatic anal cancer. These treatments may reduce symptoms and may stop the tumor from growing for a few months or longer.
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2021-12-14T09:39:02</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Anus</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-GY024</PROTOCOL_NO>
    <TITLE>Gronigen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial</TITLE>
    <NCT_ID>NCT05076942</NCT_ID>
    <SHORT_TITLE>Gronigen International Study on Sentinel Nodes in Vulvar Cancer: A Prospective Phase II </SHORT_TITLE>
    <INVESTIGATOR_NAME>Krishnansu Tewari</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Sexes Eligible for Study:	Female
18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

Histological confirmed primary SCC of the vulva
-T1 tumor, not encroaching urethra/vagina/anus
-Depth of invasion &gt; 1mm
-Tumor diameter &lt; 4cm
-Unifocal tumor
-No enlarged (&gt;1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound)
-Possibility to obtain informed consent
-Metastatic sentinel lymph node; size of metastasis &gt; 2mm and / or extracapsular extension, or
-Metastatic sentinel lymph node: more than 1 SN with metastasis greater than or equal to 2mm
-Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures
-Adequate bone marrow, renal and liver function:
-Absolute neutrophil count greater than or equal to  1.5 x 109 /L
-Platelet count greater than or equal t 100 x 109 /L
-Creatinine clearancegreater than or equal to  40 ml/min measured by the Cockroft Gault formula
-Total bilirubin &lt; 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) greater than or equal to 2.5 x ULN
-Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A)
-Age 18 years or older
-Life expectancy of greater than or equal to12 weeks
-Written informed consent

Exclusion Criteria:

-Inoperable tumors and tumors &gt; 4cm
-Multifocal tumors
-Tumors with other pathology than squamous cell carcinoma
-Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology
-No other carcinomas, other than basal cell carcinomas, within last 5 years
-History of pelvic radiotherapy
-History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment
-Pregnant female or nursing mother
-Desire to become pregnant
-Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids
-Unstable angina, myocardial infarction, cerebrovascular accident, &gt; Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Vulvar cancer patients with SN-metastasis &gt; 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-06-03T11:12:49</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-189</PROTOCOL_NO>
    <TITLE>A Multicenter, Open-Label, Phase II Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors</TITLE>
    <NCT_ID>NCT05007106</NCT_ID>
    <SHORT_TITLE>Ph II  MK-7684A w/ or w/o Other Anticancer Therapies in Participants w/ Selected Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Krishnansu Tewari</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>-18 Years and older   (Adult, Older Adult)</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

One of the following histologically or cytologically confirmed, advanced (locally recurrent unresectable or metastatic) solid tumors:

-Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
-Endometrial cancer
-Head and neck swuamous cell carcinoma (HNSCC)
-Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
-Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
-Triple-negative breast cancer (TNBC)
-Hepatocellular carcinoma (HCC)
-Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
-Adequately controlled blood pressure (BP) with or without antihypertensive medications.
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
-Male participants must agree to follow contraceptive guidance.
-Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
-Adequate organ function.

Exclusion Criteria:

-History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
-Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
-Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
-Active autoimmune disease that has required systemic treatment in past 2 years.
-Active infection requiring systemic therapy.
-Concurrent active hepatitis B and hepatitis C virus infection.
-History of allogenic tissue/solid organ transplant.
-Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
-History of congestive heart failure or myocardial infarction within 6 months of treatment (for participants who will receive paclitaxel in their assigned allocation arm).</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-04-29T16:36:45</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Merck Sharp &amp; Dohme Corp.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-193</PROTOCOL_NO>
    <TITLE>A Phase IB/III Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with FGFR2b Overexpression</TITLE>
    <NCT_ID>NCT05111626</NCT_ID>
    <SHORT_TITLE>PhI/IIIBemarituzumab + Chemo &amp;Nivo vsChemo &amp; Nivo in Subj w/Prev Untreat Adv Gastric &amp; GEC w/FGFR2b </SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
Adult with unresectable, locally advanced or metastatic (not amenable to curative therapy) histologically documented gastric or gastroesophageal junction adenocarcinoma.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Measurable disease or non-measurable, but evaluable disease, according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1)
You must have no contraindications to mFOLFOX6 chemotherapy or nivolumab

Exclusion Criteria:
Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway
Known positive human epidermal growth factor receptor 2 (HER2) status
Untreated or symptomatic central nervous system disease metastases and leptomeningeal disease
Peripheral sensory neuropathy grade 2 or higher
Clinically significant cardiac disease
Other malignancy within the last 2 years (exceptions for definitively treated disease)
Chronic or systemic ophthalmologic disorders
Major surgery or other investigational study within 28 days prior to randomization
Palliative radiotherapy within 14 days prior to randomization
Abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.

The main objective Part 2 is to compare efficacy of bemarituzumab plus mFOLFOX6 and nivolumab to placebo plus mFOLFOX6 and nivolumab as assessed by overall survival.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T08:48:04</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-184</PROTOCOL_NO>
    <TITLE>A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies</TITLE>
    <NCT_ID>NCT05332054</NCT_ID>
    <SHORT_TITLE>A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies</SHORT_TITLE>
    <INVESTIGATOR_NAME>Susan O'Brien</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- you or your legal representative can sign the informed consent


</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.
</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Other</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-25T17:37:43</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Caribou Biosciences, Inc. </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-204</PROTOCOL_NO>
    <TITLE>A Phase IIa, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)</TITLE>
    <NCT_ID>NCT05143957</NCT_ID>
    <SHORT_TITLE>PhIIa of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)</SHORT_TITLE>
    <INVESTIGATOR_NAME>Angela G Fleischman</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The main purpose of this study is to evaluate the efficacy of IONIS-TMPRSS6-LRx in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-11T12:27:29</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Ionis Pharmaceuticals</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>COG-ANHL1931</PROTOCOL_NO>
    <TITLE>A Randomized Phase III Trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma</TITLE>
    <NCT_ID>NCT04759586</NCT_ID>
    <SHORT_TITLE>PhIII Nivolumab in Combo w/ Chemo for the Tx of Newly Diagnosed Primary Mediastinal B-cell Lymphoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- are must be &amp;#8805; 2 years of age



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Both</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-02-07T11:37:52</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>CHILDREN¬íS ONCOLOGY GROUP</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-GU009</PROTOCOL_NO>
    <TITLE>Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk And Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (Predict-Rt*)</TITLE>
    <NCT_ID>NCT04513717</NCT_ID>
    <SHORT_TITLE>Parallel Ph III for High Risk Prostate Ca Evaluating De-Intensification &amp; Intensification of Tx</SHORT_TITLE>
    <INVESTIGATOR_NAME>Steven Neema Seyedin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration
- The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug

Exclusion Criteria: 
- Prior systemic chemotherapy within =&lt; 3 years prior to registration; note that prior chemotherapy for a different cancer is allowed (completed &gt; 3 years prior to registration)
- Prior radical prostatectomy
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-11T11:33:32</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES>
      <THERAPY_NAME>Radiotherapy</THERAPY_NAME>
    </THERAPY_NAMES>
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-206</PROTOCOL_NO>
    <TITLE>A Prospective, Multicenter, Open-Label Single Arm Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres Y-90 Resin Microspheres on Duration of Response (DoR) and Objective Response Rate (ORR) in Unresectable Hepatocellular Carcinoma (HCC) Patients (DOORwaY90 Study)</TITLE>
    <NCT_ID>NCT04736121</NCT_ID>
    <SHORT_TITLE>SIRT Using SIR-Spheres Y-90 Resin Microspheres on DoR &amp; ORr in Unresectable HCC Patients </SHORT_TITLE>
    <INVESTIGATOR_NAME>Nadine Abi-Jaoudeh</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Participants must be 18 or older at the time of consent.
-Participants must be willing, able, and mentally competent to provide written informed consent
- Participants must have a negative serum pregnancy test at baseline


Exclusion Criteria:
- Participants who have prior systemic anti-cancer therapy (including immunotherapy and/or targeted therapy), radiotherapy or use of other investigational agents for the treatment of HCC
-Participants who have planned localized cancer treatment to the liver, other than the study treatment, throughout the duration of the study
- Participants with prior liver resections and/or liver transplant</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.

SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a size between 20 and 60 microns in diameter. Y-90 is a high-energy pure beta-emitting isotope with no primary gamma emission.

SIR-Spheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1 and B2, maximal single lesion size of 8 cm, no macrovascular invasion, well-compensated liver function and good performance status. It is also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of Floxuridine (FUDR).</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-04-06T12:40:00</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Sirtex Medical Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-208</PROTOCOL_NO>
    <TITLE>AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS</TITLE>
    <NCT_ID>NCT04553692</NCT_ID>
    <SHORT_TITLE>Ph I Study of IGM-8444 as a Single Agent &amp; in Combo in Subjects w/ Relapsed &amp;/or Refr Solid Cancers</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>You can participate in this study if you are at least 18 years of age or older; have been clinically diagnosed with of locally advanced or metastatic cancer. You cannot participate in this study if you are pregnant or breast feeding; if you are using medication well known to cause liver toxicity.</DETAILED_ELIGIBILITY>
    <DESCRIPTION />
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-10-17T12:12:22</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>IGM Biosciences, Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-212</PROTOCOL_NO>
    <TITLE>A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1</TITLE>
    <NCT_ID>NCT05382286</NCT_ID>
    <SHORT_TITLE>Ph III Study of Sacituzumab Govitecan + Pembro v. Dr. Choice + Pembro in Pts w/ Trip-Neg Breast Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria
-Participants must be at least 18 years of age
-Participants must have locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
-Male and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.

Exclusion Criteria
-Participants who are pregnant or lactating
-Participants who have received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.
-Participants who have active serious infection requiring antibiotics.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-27T11:05:02</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Gilead Sciences, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-209</PROTOCOL_NO>
    <TITLE>A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</TITLE>
    <NCT_ID>NCT04965493</NCT_ID>
    <SHORT_TITLE>PhIII Pirtobrutinib + Venetoclax &amp; Rituximab vs Venetoclax &amp; Rituximab in PrevTreated CLL/SLL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Catherine Coombs</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>You have been diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and have previously received at least one treatment that may include a BTK inhibitor for your disease and:
did not respond to that treatment, or
initially responded but your CLL/CLL later progressed on that treatment, or; 
experienced side effects that made it difficult to continue that treatment or
the decision to stop that treatment was made by you and your study doctor</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-28T13:07:37</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Loxo Oncology, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S2104</PROTOCOL_NO>
    <TITLE>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</TITLE>
    <NCT_ID>NCT05040360</NCT_ID>
    <SHORT_TITLE>PhII Postop Adj Capecitabine &amp; Temozolomide vs Obs in High-Risk Pancreatic Neuroendocrine Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 90 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam
Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report
Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be &gt;= 3% and =&lt; 55%. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria
Participants with localized resected pNETS must have a Zaidi score of &gt;= 3 derived by the following factors and points:
1 point; symptomatic tumor defined as one of the following:
Gastrointestinal bleed
Jaundice
Gastrointestinal obstruction
Pain from primary tumor prior to surgical resection
Pancreatitis
2 points; primary pancreas tumor size &gt; 2 cm
1 point; Ki-67 3% to 20%
1 point; lymph node positivity = 1
6 points; Ki-67 21% to 55%
Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection
Participants must have recovered from effects of surgery as determined by the treating investigator
Participants must be &gt;= 18 years old
Participants must have Zubrod performance status of 0-2
Participants must have a complete medical history and physical exam within 28 days prior to registration
Leukocytes &gt;= 3 x 10^3/uL (within 28 days prior to registration)
Absolute neutrophil count &gt;= 1.5 x 10^3/uL (within 28 days prior to registration)
Platelets &gt;= 100 x 10^3/uL (within 28 days prior to registration)
Total bilirubin =&lt; institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =&lt; 5 x institutional ULN (within 28 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3 x institutional ULN (within 28 days prior to registration)
Serum creatinine =&lt; 1.5 x institutional ULN (within 28 days prior to registration)
Calculated creatinine clearance &gt;= 50 ml/min (within 28 days prior to registration)
Participants must be able to swallow pills
Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol
No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:
Participants must not have unresected or unablated metastatic disease
Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis
Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-07T09:10:39</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-218</PROTOCOL_NO>
    <TITLE>A Phase IB Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)</TITLE>
    <NCT_ID>NCT05267470</NCT_ID>
    <SHORT_TITLE>PhIB of Bemarituzumab Monotherapy &amp; Combo w/ Docetaxel in Subjects w/ Squamous-Cell NSCLC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Inclusion Criteria:

Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures
Age &amp;#8805; 18 years old (or legal adult within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed
Pathologically confirmed squamous cell lung carcinoma
Disease that is unresectable, locally advanced or metastatic (not amenable to curative therapy)
Participant must have progressed on, or recurred after at least 1 prior systemic therapy (Part 1 and 2 only) or at least 2 prior systemic therapies (Part 3 only) for locally advanced and unresectable or metastatic disease. Prior treatment must include a platinum-based doublet chemotherapy and checkpoint inhibitor for advanced or metastatic disease, either given as one line of therapy or as individual lines of therapy, unless the participant has a medical contraindication to one of the required therapies (which must be documented in the electronic case report form [eCRF]). Additionally, if the participant's tumor was previously identified as having a driver mutation (according to local standard of care or guidelines, e.g., Kirsten rat sarcoma [KRAS] G12C, neurotrophic tyrosine receptor kinase [NTRK]), which has an approved therapy for which the participant is eligible and available, the participant must have received the approved therapy in a prior line of treatment.
For Part 4, participants may not have received prior systemic therapy for their locally advanced and unresectable or metastatic disease. For Part 4, participants who received peri-operative systemic therapy are eligible if that adjuvant/neoadjuvant therapy was completed at least 12 months prior to diagnosis of locally advanced and unresectable or metastatic disease.
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ function as determined per protocol
Part 2, 3 and 4 only: FGFR2b overexpression as determined by centrally performed immunohistochemistry (IHC) testing</ELIGIBILITY>
    <DESCRIPTION>18 Years to 99 Years   (Adult, Older Adult)</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-28T20:31:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-220</PROTOCOL_NO>
    <TITLE>An Open-Label, Multicenter, Phase II Study of Sacituzumab Govitecan Combinations in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations</TITLE>
    <NCT_ID>NCT05186974</NCT_ID>
    <SHORT_TITLE>PhIISacituzumab Govitecan Combos in 1st-Line Tx of Pts w/Adv or Met NSCLC w/oActionable Genome Alter</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>If you decide to take part in this study, there are some rules you must follow.  Some of the rules are listed below.  There could be other rules that your study doctor will review with you.

1. You must not get pregnant or get someone pregnant during this study.
2. It is very important that you tell your study doctor all of the information you know about your health and medications you are taking now or start taking while in the study.  If you do not tell the study doctor everything you know, you may be putting your health at risk.
3. You are not allowed to take certain medications while in the study treatment phase of this study. Please consult with your study doctor to see what medications you may not take.
4. You must follow all instructions given to you while you are taking part in this study.  If you do not, you may no longer be able to take part in the study.  If you are unsure about what you are supposed to do, ask your study doctor.
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-08-15T17:26:55</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Gilead Sciences, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-222</PROTOCOL_NO>
    <TITLE>A Novel Method for Treating Lung Metastases with the Combination of Electrical Fields and Radiation Therapy: A Single-Arm Pilot Study </TITLE>
    <NCT_ID>NCT05555342</NCT_ID>
    <SHORT_TITLE>A Novel Method for Treating Lung Met w/Combo of Electric Fields &amp; Rad Therapy: A Single-Arm </SHORT_TITLE>
    <INVESTIGATOR_NAME>Jeremy Harris</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
-18 years of age or older 
- Patients must have histologically or cytologically confirmed metastatic cancer of any histology and have at least one lung tumor
Patients must have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

Exclusion Requirements
You cannot participate in this study if you satisfy the following criteria:
- Pregnant or nursing
- Receiving any other investigational agents</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.</DESCRIPTION>
    <PHASE_DESC>Early Phase I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-01-06T12:12:35</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES>
      <THERAPY_NAME>Radiotherapy</THERAPY_NAME>
    </THERAPY_NAMES>
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-224</PROTOCOL_NO>
    <TITLE>A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinectics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors</TITLE>
    <NCT_ID>NCT05225584</NCT_ID>
    <SHORT_TITLE>PhI KT-333 in Adult Patients w/ R/R Lymphomas, Large Granular Lymphocytic Leukemia, &amp; Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lauren C Pinter-Brown</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you
- must be 18 years of age or older



Exclusion Requirements.
You cannot participate in this study if you
- are pregnant or breast-feeding</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), and solid tumors.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-21T10:02:14</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Kymera Therapeutics</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-225</PROTOCOL_NO>
    <TITLE>A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinectics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma</TITLE>
    <NCT_ID>NCT05364424</NCT_ID>
    <SHORT_TITLE>PhIBGlofitamab Combo w/Rituximab+Ifosfamide CarboplatinEtoposidePhosphate in Pts w/R/R TransEligDBCL</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lauren C Pinter-Brown</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have failed one prior line of therapy incorporating an anti-cluster of differentiation (CD) 20 antibody (i.e., rituximab) and an anthracycline, and who are transplant or chimeric antigen receptor T-cell (CAR-T) therapy eligible, defined as being medically eligible for intensive platinum-based salvage therapy followed by autologous stem cell transplantation (ASCT) or for CAR-T therapy.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-16T09:11:58</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>F. Hoffmann-La Roche Ltd</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S2001</PROTOCOL_NO>
    <TITLE>Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations</TITLE>
    <NCT_ID>NCT04548752</NCT_ID>
    <SHORT_TITLE>PhII Olaparib + Pembrolizumab vs. Olaparib in Met Pancreatic Ca Pts w /Germline BRCA1 or BRCA2 Mut</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

- Patient must have histological or cytological diagnosis of pancreatic adenocarinoma.
- Patient must have one of the following mutations: germline mutation in BRCA 1 or 2 from a CLIA certified lab defined as positive and/or deleterious (pathogenic or likely pathogenic variant).
- Patient must have metastatic disease and received first line platinum-based chemotherapy (i.e. FOLFIRINOX, FOLOFX, gemcitabine + nab-paclitaxel + cisplatin or gemcitabine + cisplatin). </DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to compare the usual treatment (olaparib) alone to using pembrolizumab plus the usual treatment.  The addition of pembrolizumab to the usual treatment could help to shrink your cancer   but, it could also cause side effects. This study will help the study doctors find out if this different approach is  better, the same, or worse than the usual approach.  To decide if it is better, the study doctors will be looking to see if the study drug pembrolizumab increases the time it takes for the cancer to grow  by 5 months or more compared to the usual approach.  

Olaparib alone has been approved as maintenance therapy for patients with germline BRCA1 or BRCA2 mutated pancreatic cancer. </DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-02-23T12:07:43</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-229</PROTOCOL_NO>
    <TITLE>Phase I, Open-Label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients with Advanced Solid Tumor</TITLE>
    <NCT_ID>NCT05038150</NCT_ID>
    <SHORT_TITLE>Ph I, Preliminary Efficacy Modified Salmonella Typhimurium SGN1 Pts Adv Solid Tumor</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
1. Age 18-75 years inclusive of end value, regardless of gender.
2. Part 1: Patients with advanced stage (unresectable or metastatic) cancer including but not limited to small cell lung cancer, non-small cell lung cancer (adeno- and squamous), Hodgkin's lymphoma or non-Hodgkin's lymphoma, sarcoma, cervical carcinoma, melanoma, head and neck cancer, breast cancer, ovarian cancer, pseudomyxoma peritoneum (Pseudomyxoma peritonei, PMP) and hepatocellular carcinoma characterized by failure of standard treatment (disease progression or intolerance, such as chemotherapy, targeted therapy, and other immunotherapies) or patients who have no standard treatment or patients who are unable to receive standard treatment.

Part 3: Patients who meet all the standards above and should be the selected tumor type according to part1&amp;2.

3. Patients must be able to follow up after the treatment.

Exclusion Criteria: 
1. Currently using antibiotic.
2. Tumors in hollow organs (Stomach, esophagus, intestine, urinary tract etc.).
3. Vaccination within 28 days of the first trial treatment, except for administration of inactivated vaccines and RNA vaccines (e.g., inactivated influenza vaccines and COVID-19 RNA vaccines)</DETAILED_ELIGIBILITY>
    <DESCRIPTION>To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1, a genetically modified strain of Salmonella enterica, serotype typhimurium that expresses L-Methioninase,in participants with refractory solid tumors. 

The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. 

The treatment populations shall be patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-28T16:15:43</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Guangzhou Sinogen Pharmaceutical Co., Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-239</PROTOCOL_NO>
    <TITLE>An Open-Label, Phase IB Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndrome (LR MDS) Who are Refractory/Resistant to Prior Therapies </TITLE>
    <NCT_ID>NCT05308264</NCT_ID>
    <SHORT_TITLE>Ph IB Study of R289 in Pts w/ LR MDS Who are Refractory/Resistant to Prior Therapies</SHORT_TITLE>
    <INVESTIGATOR_NAME>Piyanuch Kongtim</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>If you decide to participate in the study, some tests will be done to see if you are eligible. If the test results show that you meet the study requirements, then you will be able to start the study. If the test results show that you do not meet the study requirements, you will not be able to participate. </DETAILED_ELIGIBILITY>
    <DESCRIPTION>The study will be an open-label, Phase 1b study of R289 to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed, refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-01T13:33:57</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Rigel Pharmaceuticals, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-241</PROTOCOL_NO>
    <TITLE>A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)</TITLE>
    <NCT_ID>NCT05384626</NCT_ID>
    <SHORT_TITLE>Ph I/II Study of NVL-655 Patients with Advanced NSCLC and Other Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Criteria:

1. Age = or &gt; 18 years
2. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.
3. Phase 2
a. Cohorts 2a, 2b, and 2c: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
b. Cohort 2d: histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation
4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1
5. Adequate organ function and bone marrow reserve

Exclusion criteria:
1. Patient's cancer has a known oncogenic driver alteration other than ALK.
2. Known allergy/hypersensitivity to excipients of NVL-655.
3. Major surgery within 4 weeks of the study entry
4. Ongoing or anticancer therapy
5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.

Phase 1 will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.

Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-09T16:40:25</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Nuvalent, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-247</PROTOCOL_NO>
    <TITLE>A First-in-Human, Multicenter, Open-Label, Phase I Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies Including Lymphoma</TITLE>
    <NCT_ID>NCT04137900</NCT_ID>
    <SHORT_TITLE>Ph I study of TAB004 as Monotherapy &amp;in Combo w/ Toripalimab in Pts w/Adv Solid Tumors inc. Lymphoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults with advanced unresectable or metastatic solid tumors or relapsed/refractory lymphoma.
</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion
- Male or female; 18 years or older
- Patients with histologically or cytologically confirmed advanced unresectable or metastatic solid tumors or lymphoma that have progressed following prior treatment.
- Adequate organ and marrow function. 
- Willingness to provide an archival tumor sample obtained within the past 2 years or agreement to undergo a pre-treatment biopsy from safely accessible lesions to provide a tumor sample if such an archival specimen cannot be provided. For patients who cannot provide a fresh pre-treatment biopsy, and a recent sample from the past 2 years is not available, the most recent accessible archival specimen will be required. 
- Females of childbearing potential who are sexually active with a non-sterilized male partner must use effective contraception from time of screening, and must agree to continue using such precautions for 90 days after the final dose of TAB004 or toripalimab; cessation of birth control after this point should be discussed with a responsible physician.
- Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as at least 12 months with no menses confirmed by follicle-stimulating hormone [FSH] levels.
- Patients must use effective contraception. 
- Non-sterilized males who are sexually active with a female partner of childbearing potential must use effective contraception from Day 1 and for 90 days after the receipt of the final dose of TAB004 or toripalimab.

Exclusion 
- Pregnant or breastfeeding women. 
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study. 
- Any concurrent anti-cancer therapy, such as but not limited to chemotherapy, targeted therapy, radiotherapy, immunotherapy, or biologic therapy. 
- Receipt of any investigational anticancer therapy within 28 days prior to the first dose of TAB004.
- Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of TAB004. 
- Prior exposure to anti-BTLA or anti-HVEM antibodies.
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation. 
- Patients with another malignancy that has not been curatively treated.
- Major surgery within 28 days prior to first dose of TAB004.
- Unresolved toxicities from prior anticancer therapy. 
- Active or prior documented autoimmune disease. 
- Clinically significant (intracranial, gastrointestinal) bleeding within 2 weeks prior to screening. 
- Known history of tuberculosis. 
- History of or current drug-induced interstitial lung disease or pneumonitis. 
- Subjects who have discontinued prior immune therapy due to immune mediated adverse reaction(s). 
- Known to be human immunodeficiency virus (HIV) positive. 
- Evidence of hepatitis B or C virus infection.
- Active or prior documented inflammatory bowel disease (e.g., Crohn&amp;#8217;s disease, ulcerative colitis).
- History of anaphylaxis or eczema that cannot be controlled with topical corticosteroids. 
- Adult asthma that is moderate or severe, or asthma.
- Uncontrolled intercurrent illness.
- Untreated central nervous system (CNS) and leptomeningeal metastases or requiring ongoing treatment for these metastases, including corticosteroids. 
- Receipt of live attenuated vaccination within 28 days prior to study entry or within 30 days of receiving TAB004. </DETAILED_ELIGIBILITY>
    <DESCRIPTION />
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-15T13:18:37</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>TopAlliance Biosciences, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Lymphoid Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Hodgkin's Lymphoma</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-233</PROTOCOL_NO>
    <TITLE>A Phase II Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor</TITLE>
    <NCT_ID>NCT04681131</NCT_ID>
    <SHORT_TITLE>BA3011 Alone &amp; in Combinationw/Nivolumab in Adult Patientsw/Met on a PD-1/L1, EGFR, or ALK Inhibitor</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>You need to have the following exams, tests or procedures to find out if you can be in the study:

- You will be asked about your health history including any surgeries you've had and the treatments you've received for your cancer. 
- Complete physical exam 
- Performance status assessment, to see how able you are to perform your daily activities. 
- Measurement of your height and weight
- Vital sign measurements, including blood pressure, heart rate, breathing (respiratory) rate, and body temperature.
- Routine blood tests [about 13 mL or 2 ¬Ω teaspoons of blood (in total)] to test your:

- blood counts (white blood cells, red blood cells, etc.),
- liver, kidney, and thyroid function,
- cholesterol while fasting (no food within 6 hours),
- blood clotting ability.

- Blood test [about 1.5 mL or ¬º teaspoon of blood] for specific viruses, including hepatitis B and hepatitis C, and HIV. If you have positive test results for HIV or Hepatitis B or C, we will notify you. We are required to notify state health authorities of positive results.
- Routine urine testing
- Blood or urine test for pregnancy, if you are a woman who is capable of childbearing (unless you have had a hysterectomy or your tubes tied, or you are in menopause and your last menstrual period was at least 1 year ago). 
 
- Evaluation of the location and size of your cancer will be performed. 

- Your doctor may use different types of imaging, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), clinical exam or some combination of these tests.

- Electrocardiogram (ECG): a test that measures the electrical activity of your heart by using electrodes placed on your body. This assessment is not invasive which means that it does not involve the introduction of instruments or other objects into the body or body cavities.
-You will be asked about all medications (including over-the-counter and herbal remedies) you are taking and have taken in the past month.
- You will be asked to describe any symptoms you are currently experiencing.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-08T16:37:50</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bioatla</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-21-234</PROTOCOL_NO>
    <TITLE>An Open-label, Randomized, Multicenter, Phase III Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)</TITLE>
    <NCT_ID>NCT05048797</NCT_ID>
    <SHORT_TITLE>Trastuzumab Deruxtecan, NSCLC Harboring HER2 Exon 19 or 20 Mutations</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults </ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Participants at least 18 years of age
-Locally advanced not amenable to curative therapy, or metastatic disease
-Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA
-Treatment-na√Øve for palliative intent systemic therapy for locally advanced or metastatic disease
-Left ventricular ejection fraction (LVEF) &amp;#8805; 50%
-Measurable disease assessed by Investigator based on RECIST 1.1
-Protocol-defined adequate organ function including cardiac, renal, hepatic function
-ECOG 0-1
-Having tumour tissue available for central testing

Exclusion Criteria:

-Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy)
-Any clinically active brain metastases; previously treated brain metastases allowed
-Active autoimmune or inflammatory disorders
-Medical history of myocardial infarction within 6 months prior to randomization
-History of non-infectious pneumonitis/ILD, current or suspected ILD
-Lung-specific intercurrent clinical significant severe illness
-Contraindication to platinum-based doublet chemotherapy or pembrolizumab</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Eligible participants will be those diagnosed with unresectable, locally advanced or metastatic histologically documented non-squamous NSCLC with HER2 exons 19 or 20 mutations and who are treatment-na√Øve for palliative intent systemic therapy for locally advanced or metastatic disease.

The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) as compared with Standard of Care treatment (Investigator's choice of cisplatin or carboplatin + pembrolizumab + pemetrexed). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse or simply to live longer, compared to patients receiving standard of care treatment. This study is also looking to see how the treatment and the cancer affects patients' quality of life.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-10-21T12:43:16</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>AstraZeneca</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-01</PROTOCOL_NO>
    <TITLE>A Phase III Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma</TITLE>
    <NCT_ID>NCT05371093</NCT_ID>
    <SHORT_TITLE>PhIII of Axicabtagene Ciloleucel vs SOC Therapy in Subj w/ Relapsed/Refractory Follicular Lymphoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Elizabeth A Brem</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female 18 years of age at signing of the informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-04-03T14:51:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Kite Pharma</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-07</PROTOCOL_NO>
    <TITLE>A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma</TITLE>
    <NCT_ID>NCT05322590</NCT_ID>
    <SHORT_TITLE>BXQ-350 in Combination w/mFOLFOX7 &amp; Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Fa Chyi Lee</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
8 years of age at the time of signing the informed consent.
You have newly diagnosed Stage IV metastatic adenocarcinoma of the colon / rectum.
You have a life expectancy &gt; 3 months.
You have acceptable liver function defined as:
Total serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for the study site; in participants with known Gilbert Syndrome, total bilirubin less than or equal to; 3 x ULN, with direct bilirubin less than or equal to; 1.5 x ULN).
Aspartate transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT), alanine transaminase (ALT), serum glutamic pyruvic transaminase (SGPT) less than or equal to; 3 x ULN (if liver metastases are present, then less than or equal to; 5 x ULN is allowed).
Serum albumin greater than or equal to; 3 g/ dL.
You have acceptable renal function defined as:
Creatinine clearance greater than or equal to; 50 mL/minute calculated using the Cockcroft-Gault formula (Cockcroft 1976): CCr = {((140 - age) x weight kg) / (72 x SCr)} x 0.85 (if female).
Urine dipstick protein &lt; 1 + (30 - 70 mg/dL), urine protein/creatinine ratio of &lt; 1, OR 24 hour urine protein &lt; 1g/24 hours.
You have acceptable bone marrow function defined as:
Absolute neutrophil count greater than or equal to 1,500 cells / mm3.
Platelet count greater than or equal to 100,000 cells / mm3 (unsupported, no transfusion within 7 days of enrollment).
Hemoglobin &gt; 9.0 g/dL (unsupported, no transfusion within 7 days of enrollment).
You have acceptable coagulation parameters (anti-coagulation allowed) defined as:
International normalized ratio less than or equal to 2 x ULN unless on anticoagulation or prothrombin time within normal limits.
Activated partial thromboplastin time within normal limits.
You have a negative serum pregnancy test result at screening (females of childbearing potential [FCBP] only). Not applicable to participants who are surgically sterile (i.e., bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or who are post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. FCBP whose partner(s) are non-sterilized males and non-sterilized male participants whose sexual partner(s) are FCBP must abstain from heterosexual activity or agree to use an acceptable method of contraception according to the following guidelines:
The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the entire period of risk associated with study interventions and the preferred and usual lifestyle of the participant. Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods), the rhythm method, and withdrawal are not acceptable methods of contraception.
Non-sterilized Male Participants:
Must use an acceptable method of contraception such as male condom plus spermicide during the entire period of risk associated with study interventions which includes the total duration of the study and the drug washout period (6 months after the last dose of study intervention) and refrain from sperm donation or banking throughout this period.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-07-22T10:22:36</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bexion Pharmaceuticals, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-10</PROTOCOL_NO>
    <TITLE>A Phase II/III, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer</TITLE>
    <NCT_ID>NCT05141721</NCT_ID>
    <SHORT_TITLE>GRT-C901/GRT-R902, A Neoantigen Vaccine, for Pts W/Metastatic Colorectal Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Fa Chyi Lee</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
You have histologically confirmed metastatic colorectal cancer (CRC) who are planned for, or have received &lt;30 days of first-line treatment in the metastatic setting with FOLFOX/bev, CAPEOX/bev, FOLFOXIRI/bev, or CAPOXIRI/bev per SOC
Measurable and unresectable metastatic disease according to RECIST v1.1
Availability of formalin-fixed paraffin-embedded (FFPE) tumor specimens.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You have adequate organ function per defined criteria
If you are of childbearing potential (WCBP), you must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 150 days after last investigational study treatment.

Exclusion Criteria:
Patients with deficient mismatch repair (dMMR) or microsatellite instability (MSI-H) phenotype
Patient has a known tumor mutation burden &lt;1 non-synonymous mutations/megabase
Known DNA Polymerase Epsilon mutations
Patients with known BRAFV600E mutations
Bleeding disorder or history of significant bruising or bleeding following IM injections or blood draws
Immunosuppression anticipated at time of study treatment
History of allogeneic tissue/solid organ transplant
Active or history of autoimmune disease or immune deficiency
Patient with symptomatic or actively progressing central nervous system (CNS) metastases, carcinomatous meningitis, or has been treated with whole brain radiation
History of other cancer within 2 years with the exception of neoplasm that has undergone potentially curative therapy
Any severe concurrent non-cancer disease that, in the judgment of the Investigator, would make the patient inappropriate for the current study
Active tuberculosis or recent (&lt;2 weeks) clinically significant infection, evidence of active hepatitis B or hepatitis C, or known history of positive test for HIV
History of pneumonitis requiring systemic steroids for treatment (with the exception of prior resolved in-field radiation pneumonitis)
Myocardial infarction within previous 3 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure
Pregnant, planning to become pregnant, or nursing.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.
</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Both</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T09:54:52</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Gritstone bio, inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-24</PROTOCOL_NO>
    <TITLE>A Phase I First-in-Human Dose-Escalation and Dose-Escalation and Dose-Expansion Study of BMF-219, an Oral, Covalent, Menin Inhibitor, in Adult Patients with Acute Leukemia (AL), Diffuse Large B-Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)</TITLE>
    <NCT_ID>NCT05153330</NCT_ID>
    <SHORT_TITLE>PhI BMF-219 in Adult Patients w/ AL, DLBCL, &amp; MM </SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements
You can participate in this study if you are a male or female ages &amp;#8805; 55 years at the time of informed consent.

Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic leukemia with KMT2A/ MLL1r, NPM1 and other mutations.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-07T20:36:20</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Biomea Fusion, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Leukemia, other</DISEASE_SITE>
      <DISEASE_SITE>Non-Hodgkin's Lymphoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-26</PROTOCOL_NO>
    <TITLE>Open-Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors</TITLE>
    <NCT_ID>NCT03863145</NCT_ID>
    <SHORT_TITLE>Ph I Study of CB-03-10 with in Subjects with Advanced Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>INCLUSION CRITERIA:

Signed informed consent For Part 1 (Dose Escalation): Histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic solid tumor, not amenable to standard therapy For Part 2 (Dose Expansion): Histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic solid tumor limited to a specific tumor subtype as determined by the SRC Age &gt;18 years Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 For Part 1 (Dose Escalation): Measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria For Part 2 (Dose Expansion): Measurable disease as per RECIST v1.1 criteria. Adequate renal, hepatic and bone marrow function as defined by Screening labs Negative pregnancy test for females of childbearing potential at the Screening Visit and use of appropriate method of birth control.

EXCLUSION CRITERIA:

Pregnant or breastfeeding women Known central nervous system (CNS) metastases or spinal cord compression Known second cancer of other primary origin (excluding Stage I non-melanoma skin cancer and prostate cancer controlled with hormonal therapy) within the prior 5 years Active autoimmune disease Significant cardiac disease Uncontrolled hypertension Major surgery or irradiation within 28 days prior to start of study treatment Fewer than 28 days (or fewer than 5 half-lives, whichever is shorter) from prior anticancer therapy Requirement for chronic corticosteroids or other immunosuppressant drugs Known infection with hepatitis B or C virus Known infection with HIV and CD4+ T-cell counts &lt; 350 cells/uL Patients with an opportunistic infection within the past 12 months.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Subjects will undergo baseline evaluation and an assessment of extent of disease.

Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects.

Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined in the Part 1 of the study. The indications included in each group will be determined at the completion of Part 1 of the study by Safety Review Committee (SRC).

Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part 2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be re-evaluated at least 4 weeks later for confirmation.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-30T10:32:23</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Cosmo Technologies, Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-38</PROTOCOL_NO>
    <TITLE>A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)</TITLE>
    <NCT_ID>NCT05325866</NCT_ID>
    <SHORT_TITLE>A Phase Ib/II Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression </SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria
-Participants must be at least 18 years of age
-Participants must have a disease that is unresectable, locally advanced or metastatic

Exclusion Criteria
-Participants who have an active infection requiring systemic treatment or any uncontrolled infection within 14 days prior to first dose of study treatment
-Participants who are unwilling to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment
- Participants who are breastfeeding, plan to breastfeed or become pregnant while on study through 90 days after the last dose of bemarituzumab</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.</DESCRIPTION>
    <PHASE_DESC>I/II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-27T09:47:19</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Amgen Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-09</PROTOCOL_NO>
    <TITLE>A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors</TITLE>
    <NCT_ID>NCT05377996</NCT_ID>
    <SHORT_TITLE>Phase Ib Study of XMT-1660 in Solid Tumors Likely to Express B7-H4</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria
-Participants must be at least 18 years of age
-Participant has proven recurrent or advanced solid tumor and has disease progression
after treatment with available anti-cancer therapies known to confer benefit or is
intolerant to treatment
-Participant must be willing to undergo a minimally invasive tumor biopsy to obtain tumor
tissue for local testing, if medically feasible, prior to C1D1.

Exclusion Criteria
-Participant has received prior treatment with another ADC containing an auristatin or
maytansinoid payload (e.g., mirvetuxuximab)
-Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy within 14 days of starting study treatment.
-Participants with human immunodeficiency virus (HIV) infection are excluded from
study entry. An HIV test is required during Screening</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A Study of XMT-1660 in Solid Tumors</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-12-28T14:28:44</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Mersana Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-39</PROTOCOL_NO>
    <TITLE>A Phase II Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
</TITLE>
    <NCT_ID>NCT04879329</NCT_ID>
    <SHORT_TITLE>Ph II Disitamab Vedotin Alone &amp; Comb w/Pembrolizumab in Adv Unresect or Metastat Urothelial Ca HER2</SHORT_TITLE>
    <INVESTIGATOR_NAME>Nataliya Mar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Expected survival &gt;=12 weeks
- Histologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

Exclusion Criteria:
- Known hypersensitivity to disitamab vedotin, pembrolizumab (in Cohort C), or any of their components
- Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study
- Major surgery that has not fully recovered within 4 weeks prior to dose administration</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-08T09:01:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Seagen Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>CCTG-MA39</PROTOCOL_NO>
    <TITLE>Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer</TITLE>
    <NCT_ID>NCT03488693</NCT_ID>
    <SHORT_TITLE>Tailor RT: Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer</SHORT_TITLE>
    <INVESTIGATOR_NAME>Erin Heather Healy</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults 35 years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>The study population consists of women with newly diagnosed biomarker low risk node positive and T3N0 breast cancer with no evidence of metastases that have been treated by mastectomy or BCS.

Inclusion Criteria: 
- Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
- Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted.
- Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.

Exclusion Criteria: 
- Patients who are pregnant
- Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator&amp;#8217;s decision).</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-05-03T13:59:28</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Canadian Cancer Trials Group (CCTG)</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-53</PROTOCOL_NO>
    <TITLE>A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma</TITLE>
    <NCT_ID>NCT05805501</NCT_ID>
    <SHORT_TITLE>PhII Immune Checkpoint Combos w/Axitinib in Pts w/Prev Untreated Local AdvUnresec or Metastatic RCC</SHORT_TITLE>
    <INVESTIGATOR_NAME>Nataliya Mar</INVESTIGATOR_NAME>
    <STATUS>RRI SIGNOFF</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Measurable disease with at least one measurable lesion
- Negative for HIV, hepatitis B, or hepatitis C virus (HCV)

Exclusion Criteria:
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of RO7247669 and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last
- Inability to swallow a tablet or malabsorption syndrome
- Uncontrolled tumor-related pain
- Uncontrolled hypertension
- Significant cardiovascular/cerebrovascular disease within 3 months prior to randomization</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-06-02T14:41:02</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>F. Hoffmann-La Roche Ltd</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-57</PROTOCOL_NO>
    <TITLE>MAGNETISMM-17 ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY</TITLE>
    <NCT_ID>NCT05462639</NCT_ID>
    <SHORT_TITLE>Elranatamab Tx Pts w/R/R MM Ref 1 Protea Inhibit, Immuno Drug &amp;AntiCD38 &amp; No Access OtherTherapy</SHORT_TITLE>
    <INVESTIGATOR_NAME>Lisa Xingguang Lee</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult Male or female participants age &amp;#8805;18 years</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>-Prior diagnosis of Multiple Myeloma 
-Participants who are ineligible for participation in any ongoing clinical trial of elranatamab, including lack of access due to geographical limitations, and who have exhausted all other treatment options.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.

This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.</DESCRIPTION>
    <PHASE_DESC />
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-12-13T11:37:29</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Pfizer Pharmaceutical Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-59</PROTOCOL_NO>
    <TITLE>Phase III, Double-Blind, Randomized, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Patients with EGFR Mutation-Positive Stage IA2-IA3 Non-Small Cell Lung Cancer, Following Complete Tumour Resection (ADAURA2)</TITLE>
    <NCT_ID>NCT05120349</NCT_ID>
    <SHORT_TITLE>PhIII Osimertinib vs Placebo in Pts w/EGFR Mut+ Stage IA2-IA3 NSCLC Following Complete Tumour Resec</SHORT_TITLE>
    <INVESTIGATOR_NAME>Misako Nagasaka</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Male or female, at least &amp;#8805; 18 years.
NSCLC, of non-squamous histology.
Stage IA2 or IA3 disease, based on TNM8 classification.
Complete surgical resection (R0) of the primary NSCLC by lobectomy, segmentectomy or sleeve resection.
Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
World Health Organization performance status of 0 or 1.
Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas¬Æ EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne¬Æ test.
Minimum life expectancy of &gt; 6 months.
Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.</ELIGIBILITY>
    <DESCRIPTION>18 Years and older   (Adult, Older Adult)</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-02-28T20:11:44</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>AstraZeneca</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-GI008</PROTOCOL_NO>
    <TITLE>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
</TITLE>
    <NCT_ID>NCT05174169</NCT_ID>
    <SHORT_TITLE>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jason Zell</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 Years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
You must have an ECOG performance status of 0 or 1.
You must have histologically/pathologically confirmed colon adenocarcinoma (T1-3, N1/N1c) with R0 resection accordingly to AJCC 8th edition criteria. NOTE: Patients with pathologic stages II or IIIC colon adenocarcinoma with R0 resection who have a commercially obtained Signatera&amp;#8482; ctDNA+ve assay result post-operatively meeting all timelines and eligibility requirements otherwise, are eligible for enrollment and inclusion in Cohort B.
You must have no radiographic evidence of overt metastatic disease within 28 days prior to study entry (CT with IV contrast or MRI imaging is acceptable and must include chest, abdomen, and pelvis).
The distal extent of the tumor must be greater than or equal to 12 cm from the anal verge on colonoscopy or above the peritoneal reflection as documented during surgery or on pathology specimen (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation).
You must have had an en bloc complete gross resection of tumor (curative resection). Patients who have had a two-stage surgical procedure, to first provide a decompressive colostomy and then in a later procedure to have the definitive surgical resection, are eligible.

Exclusion Criteria:
Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).
Pathologic, clinical, or radiologic overt evidence of metastatic disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.
Tumor-related bowel perforation.
History of prior invasive colon malignancy, regardless of disease-free interval.
History of bone marrow or solid organ transplantation (regardless of current immunosuppressive therapy needs). Bone grafts, skin grafts, corneal transplants and organ/tissue donation are not exclusionary.
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas for which treatment with neoadjuvant chemotherapy and/or radiation is warranted are not permitted).
Other invasive malignancy within 5 years before study entry. Exceptions are colonic polyps, non-melanoma skin cancer or any carcinoma-in-situ.
Synchronous primary rectal and/ or colon cancers.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-08-10T14:24:20</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-78</PROTOCOL_NO>
    <TITLE>A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors</TITLE>
    <NCT_ID>NCT05240898</NCT_ID>
    <SHORT_TITLE>A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Krishnansu Tewari</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Adequate bone marrow and organ function at baseline
-Life expectancy of &gt;12 weeks
-Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors who meet one of the following criteria (dose escalation only):
a. Relapsed or progressed through standard therapy
b. Have a disease for which no standard effective therapy exists
c.Not a candidate for standard effective therapy

Exclusion Criteria:
-Grade 2 or greater toxicity, except alopecia related to any prior treatment (ie, chemotherapy, targeted therapy, radiation, or surgery)
-Prior anticancer treatment including:

a. Chemotherapy or small molecule-targeted therapy &lt; 2 weeks prior to first dose of study treatment
b. Any antibody therapy &lt; 5 half-lives from first dose of study treatment (or 4 weeks since last therapy, whichever is the shortest)
c. PD-1 (anti-programmed death 1) or PD-L1 (anti-programmed death ligand 1) therapy &lt; 4 weeks from first dose of study treatment
d. Invasive surgery requiring general anesthesia &lt; 30 days from first dose of study treatment
e. Chemotherapy with nitrosoureas or mitomycin C, &lt; 45 days from first dose of study treatment
f. Radiation therapy (including radiofrequency ablation) &lt; 4 weeks prior to initiation of study treatment
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase 1 study to assess the safety and clinical activity of KSQ-4279 alone and in combination in patients with advanced solid tumors. This is a Phase 1 study consisting of 2 parts: Dose Escalation and Expansion to evaluate the safety, tolerability, clinical activity, and pharmacokinetics (PK) Study of KSQ-4279 as a Monotherapy or in Combination in Patients with Advanced Solid Tumors.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-23T09:00:18</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>KSQ Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Multiple Myeloma</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-80</PROTOCOL_NO>
    <TITLE>A Randomized, Double-Blind, Placebo-Controlled, Phase IIA Study of Topical Pirenzepine or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel</TITLE>
    <NCT_ID>NCT05488873</NCT_ID>
    <SHORT_TITLE>Topical Pirenzepine Prevention of Limiting Chemo Peripheral Neuropathy Carboplatin and Paclitaxel</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jill Tseng</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:

- Males and females, ages &gt; 18 years and older
- Ability to sign informed consent and understand the nature of a placebo-controlled trial
-If diabetic, be on stable antidiabetic treatment (&gt; 2 months prior to screening) (oral or injectable antidiabetic therapy and/or lifestyle) that is not anticipated to change during the course of the study, except if medically required.

Exclusion Criteria:

-Pre-existing history (with or without current symptoms) in medical history of any type of peripheral neuropathy due to any cause other than prior chemotherapy (diabetes, alcohol, toxins, neurotoxic treatments, hereditary, autoimmune, etc.).
- Head or neck cancers
-Scheduled to undergo radiation therapy while on study</DETAILED_ELIGIBILITY>
    <DESCRIPTION>A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study Of Topical Pirenzepine (WST-057) Or Placebo For The Prevention Of Dose Limiting Chemotherapy Induced Peripheral Neuropathy In Oncology Patients Administered Carboplatin And Paclitaxel</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-05-10T14:36:54</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Winsantor, Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>ECOG-EA2197</PROTOCOL_NO>
    <TITLE>Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial</TITLE>
    <NCT_ID>NCT04559139</NCT_ID>
    <SHORT_TITLE>Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III </SHORT_TITLE>
    <INVESTIGATOR_NAME>Zeljka Jutric</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Eligibility Criteria:

-Patients must be 18 years of age or older
-Patients must have confirmed T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease.
-Patients must have undergone initial cholecystectomy within 12 weeks</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.</DESCRIPTION>
    <PHASE_DESC>II/III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-14T08:53:21</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>ECOG-ACRIN</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Liver</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>NRG-GU011</PROTOCOL_NO>
    <TITLE>A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)</TITLE>
    <NCT_ID>NCT05053152</NCT_ID>
    <SHORT_TITLE>PhII of Prostate Oligomet Radiotherapy w/ or w/o ADT in Oligomet Prostate Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Steven Neema Seyedin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration
- The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug

Exclusion Criteria:
- Currently on androgen deprivation or anti-androgen therapy
- Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for &gt;= 3 years
- Prior chemotherapy for prostate cancer or bilateral orchiectomy</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-09-12T16:48:29</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>NRG Oncology </SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-88</PROTOCOL_NO>
    <TITLE>Phase I/IB, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors</TITLE>
    <NCT_ID>NCT05462717</NCT_ID>
    <SHORT_TITLE>PhI/IB of RMC-6291 Monotherapy in Subj w/ Advanced KRASG12C Mutant Solid Tumors</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if you :
- must be &gt; or = 18 years of age.
- must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
- ECOG performance status 0 or 1
- Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation
- Adequate organ function

Exclusion Requirements 
You cannot participate in this study if you:
- Have primary central nervous system (CNS) tumors
- Have active brain metastases
- Have known impairment of GI function that would alter the absorption
- Have major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
- Have prior therapy with KRASG12C (ON) inhibitor
Other inclusion/exclusion criteria may apply.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-12-19T16:56:01</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Revolution Medicines</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-87</PROTOCOL_NO>
    <TITLE>Phase I/IB Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS</TITLE>
    <NCT_ID>NCT05379985</NCT_ID>
    <SHORT_TITLE>PhI/IB of RMC-6236 in Subj w/ Adv Solid Tumors Harboring Specific Mutations in KRAS</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>IRB INITIAL APPROVAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>If you are eligible for this study and decide to take part, you will be required to do the following:

- Keep all your study appointments/visits and complete the study assessments
- Let the study staff/study doctor know about any changes in your health or medications
- Agree to using highly effective methods of birth control during this study and for at least 3 months after the last dose of the study drug if you are male and at least 1 month after the last dose of the study drug if you are female. Your study doctor will discuss what highly effective methods of contraception are with you.
- Let the study staff/study doctor know if you think you are pregnant (women) or if your partner is pregnant (men)
- Agree not to take part in another research drug study
- Let the study staff/study doctor know if you change your mind about taking part in the study
- Consider letting your regular (primary) doctor know or allowing the study doctor to notify your (primary) doctor that you are taking part in this research study, your permission will be sought at the end of this document.
- Agree to not eat grapefruit, including products containing grapefruit for 7 days before Cycle 1 Day 1 and while receiving RMC-6236.
- Agree not to use certain medications or foods that may interact with the study drug within 7 days of study drug administration on Cycle 1 Day 1. Your study doctor will let you know which medications are not allowed. Let your study doctor know if you need to start taking any new medications.
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Evaluate the safety and tolerability of RMC-6236 in adults with KRAS p.G12 mutant advanced solid tumors, KRAS p.G12C excluded.</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-03T18:41:27</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Revolution Medicines</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Mycosis Fungoides</DISEASE_SITE>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
      <DISEASE_SITE>Unknown Sites</DISEASE_SITE>
      <DISEASE_SITE>Breast</DISEASE_SITE>
      <DISEASE_SITE>Pancreas</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Lung</DISEASE_SITE>
      <DISEASE_SITE>Other Skin</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Prostate</DISEASE_SITE>
      <DISEASE_SITE>Urinary Bladder</DISEASE_SITE>
      <DISEASE_SITE>Thyroid</DISEASE_SITE>
      <DISEASE_SITE>Other Endocrine System</DISEASE_SITE>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Other Respiratory and Intrathoracic Organs</DISEASE_SITE>
      <DISEASE_SITE>Other Male Genital</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Soft Tissue</DISEASE_SITE>
      <DISEASE_SITE>Other Urinary</DISEASE_SITE>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
      <DISEASE_SITE>Liver</DISEASE_SITE>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Other Female Genital</DISEASE_SITE>
      <DISEASE_SITE>Eye and Orbit</DISEASE_SITE>
      <DISEASE_SITE>Brain and Nervous System</DISEASE_SITE>
      <DISEASE_SITE>Ill-Defined Sites</DISEASE_SITE>
      <DISEASE_SITE>Bones and Joints</DISEASE_SITE>
      <DISEASE_SITE>Cervix</DISEASE_SITE>
      <DISEASE_SITE>Corpus Uteri</DISEASE_SITE>
      <DISEASE_SITE>Kaposi's Sarcoma</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>GOG-3049</PROTOCOL_NO>
    <TITLE>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT)</TITLE>
    <NCT_ID>NCT05329545</NCT_ID>
    <SHORT_TITLE>Ph III Placebo St Upifitamab Rilsodotin Post-Platinum Ther Platinum-Sensitive Recurrent Ovarian Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jill Tseng</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
-Participant must have a histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube and primary peritoneal cancer, that is metastatic or recurrent.
-Participant must have platinum-sensitive recurrent disease, defined as having achieved either a partial or complete response to 4 or more cycles in their penultimate platinum- containing regimen and their disease progressing more than 6 months after completion of the last dose of platinum containing therapy in the penultimate regimen.
-Participant must have had as their best response to last line of treatment one of the following: No Evidence of Disease (NED); Complete Response (CR); Partial Response (PR); OR Stable Disease (SD)

Exclusion Criteria:
-Participant has history of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease. Testing beyond laboratory studies otherwise defined in the eligibility criteria, to diagnose potentially clinically significant liver disease based on risk factors such as hepatic steatosis or history of excessive alcohol intake, will be based on clinical judgement of the investigator.
-Participant has history of or suspected pneumonitis or interstitial lung disease.
-Participant has untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis, or carcinomatous meningitis.
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-23T11:04:58</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>GOG Partners</SPONSOR_NAME>
      <SPONSOR_NAME>Mersana Therapeutics, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Ovary</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-92</PROTOCOL_NO>
    <TITLE>Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis</TITLE>
    <NCT_ID>NCT05844865</NCT_ID>
    <SHORT_TITLE>Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis</SHORT_TITLE>
    <INVESTIGATOR_NAME>Maheswari Senthil</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study. 

Inclusion Requirements You can participate in this study if you
- At least 18 years of age
- Able to provide written informed consent
- Have a planned surgical procedure at UCI for your peritoneal carcinomatosis from your gastric cancer

Exclusion Requirements You cannot participate in this study if you
- Do not have peritoneal carcinomatosis from a non-gastric tumor.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.</DESCRIPTION>
    <PHASE_DESC />
    <TREATMENT_TYPE_DESC>Basic Science</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-05-04T11:04:37</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-101</PROTOCOL_NO>
    <TITLE>A Phase III, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-Dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma</TITLE>
    <NCT_ID>NCT05625399</NCT_ID>
    <SHORT_TITLE>PhIII Subcutaneous Nivolumab+Relatlimab Fixeddose Comb vsIntravenous Nivolumab+Relatlimab Melanoma</SHORT_TITLE>
    <INVESTIGATOR_NAME>Warren A Chow</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 1/Lansky Performance Score, &gt; 80% for adolescents 12 to 18 years of age).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the American Joint Committee for Cancer (AJCC) staging system.
- Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system (8th edition).

Exclusion Requirements 
- Participants must not have ocular melanoma.
- Participants must not have a history of myocarditis, regardless of etiology.
- Participants must not have a condition requiring systemic treatment with either corticosteroids (&gt;10 milligrams [mg] daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses &gt;10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Children</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-04-24T14:57:25</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Bristol-Myers Squibb</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-109</PROTOCOL_NO>
    <TITLE>A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy</TITLE>
    <NCT_ID>NCT05199818</NCT_ID>
    <SHORT_TITLE>Doubledummy EfficacyPalonosetron HCl Buccal Film IV Palonosetron0.25mg PrevenNausea Emetogenic Chemo</SHORT_TITLE>
    <INVESTIGATOR_NAME>Farshid Dayyani</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>18 years and older</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>To participate in this study, you must meet the following criteria:
Be at least 18 years of age 
Have a diagnosis of solid tumor cancer 
Be scheduled to receive chemotherapy that is known to cause nausea and vomiting
You must be able to read, understand, and follow the study procedures 
Be able to complete a subject diary on your own
Your assessed Karnofsky performance status should be not less than 50
If you have a seizure disorder that is unstable and require anticonvulsant medication, you  cannot participate in this study
If your cardiovascular system, kidney or liver is impaired, you may participate only at the discretion of the study doctor
You cannot participate if you experienced moderate to severe nausea following any previous chemotherapy unless enrolled at the discretion of the study doctor
You cannot be in the study if you have any ongoing vomiting from any organic etiology, or if you have experienced any vomiting, retching, or National Cancer Institute (NCI) common Toxicity Criteria grade 2 or 3 or nausea in the 24 hours preceding chemotherapy
If you have symptomatic primary or metastatic CNS malignancy, you cannot participate. 
You cannot participate if you will be receiving moderately-emetogenic chemotherapy or radiotherapy during Study Day 2-5 or highly-emetogenic chemotherapy or radiotherapy during Study Day 1-6 or will be receiving radiotherapy of the upper abdomen or cranium during Study Day 2
If you will be receiving bone marrow or stem cell transplant during the study, you cannot  participate</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Prevention</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-10-03T14:07:07</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Xiamen LP Pharmaceutical Co., Ltd.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Esophagus</DISEASE_SITE>
      <DISEASE_SITE>Stomach</DISEASE_SITE>
      <DISEASE_SITE>Small Intestine</DISEASE_SITE>
      <DISEASE_SITE>Other Digestive Organ</DISEASE_SITE>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
      <DISEASE_SITE>Anus</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-114</PROTOCOL_NO>
    <TITLE>A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with Exemestane Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer</TITLE>
    <NCT_ID>NCT05306340</NCT_ID>
    <SHORT_TITLE>PhIII StudyEvaluating Giredestrant+Everolimust Compare w/Exemestane+Everolimus Pts ER+HER2-Breast Ca</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria
- Patients at least 18 years old at the time of signing informed consent form
- Patients with advanced unresectable or metastatic adenocarcinoma of the breast
- Patients willing and able to use an electronic device for PRO data collection

Exclusion Criteria
- Patients with prior chemotherapy for locally advanced unresectable or metastatic disease
- Patients with any investigationaly therapy within 28 days prior to initiation of study treatment
- Patients with major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days prior to randomization</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-06-01T15:42:30</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Genentech, Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S2015</PROTOCOL_NO>
    <TITLE>S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma</TITLE>
    <NCT_ID>NCT03860883</NCT_ID>
    <SHORT_TITLE>PhIII MultiCentreMulti-NationalControl Tria Inves1cmv2cm WideExcision Margins Primary Cutaneous Mela</SHORT_TITLE>
    <INVESTIGATOR_NAME>Maki Yamamoto</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Patients must have a stage II primary invasive cutaneous melanoma </DETAILED_ELIGIBILITY>
    <DESCRIPTION>Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-11-30T13:38:46</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Melanoma, Skin</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-130</PROTOCOL_NO>
    <TITLE>OPtimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) </TITLE>
    <NCT_ID>NCT05361720</NCT_ID>
    <SHORT_TITLE>OPtimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) </SHORT_TITLE>
    <INVESTIGATOR_NAME>Nataliya Mar</INVESTIGATOR_NAME>
    <STATUS>IRB INITIAL APPROVAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
- Male or female &gt;= 18 years of age at the time of informed consent
- Patient can comprehend and sign the study informed consent form
- No prior systemic therapy for renal cell carcinoma (RCC) in the neoadjuvant, adjuvant or metastatic setting

Exclusion Criteria:
- Active infection requiring infusional treatment
- Major surgery requiring general anesthesia =&lt; 14 days before first dose of protocol-indicated treatment
- Inadequately controlled hypertension (systolic blood pressure [SBP] &gt; 160/90 mmHg)</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond.</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-06-02T14:55:09</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Vanderbilt University Medical Center</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Kidney</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-132</PROTOCOL_NO>
    <TITLE>De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx</TITLE>
    <NCT_ID>NCT05600842</NCT_ID>
    <SHORT_TITLE>Observational Study De-escalated Radiation Human PapillomavirusPos Squamous Carcinoma Oropharynx</SHORT_TITLE>
    <INVESTIGATOR_NAME>Allen Min Chen</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. 
Inclusion Requirements
You can participate in this study if you 
&amp;#8226;	Are 18 years of age or older 
&amp;#8226;	Able to provide written informed consent 
&amp;#8226;	Are diagnosed with HPV-Positive squamous cell cancer of the oropharynx

Exclusion Requirements 
You cannot participate in this study if you
&amp;#8226;	Received prior radiotherapy
&amp;#8226;	Received prior chemotherapy for the study cancer
</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.</DESCRIPTION>
    <PHASE_DESC>N/A</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>Local</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-01-06T11:58:38</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>UCI</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Larynx</DISEASE_SITE>
      <DISEASE_SITE>Lip, Oral Cavity and Pharynx</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>SWOG-S2107</PROTOCOL_NO>
    <TITLE>Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer</TITLE>
    <NCT_ID>NCT05308446</NCT_ID>
    <SHORT_TITLE>Ph II Trial Encorafenib Cetuximab w/or w/out Nivolumab Pts PreviouslyTreated MicrosatelliteBRAFV600E</SHORT_TITLE>
    <INVESTIGATOR_NAME>Jennifer Brooke Valerin</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adults</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Inclusion Criteria:
You must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum. The date of diagnosis will be determined according to the pathologic date of diagnosis
You must have measurable disease according to RECIST1.1 criteria. Computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form
You must have documented unresectable and/or metastatic disease on CT or MRI imaging. All disease must be assessed and documented on the Baseline Tumor Assessment Form
You must have BRAF^V600E mutated colorectal cancer as tested in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory
You must have proficient mismatch repair (pMMR) or microsatellite stable (MSS) status as tested in a CLIA-certified laboratory and documented by the treating clinician. Proficient mismatch repair status can be determined by intact expression by immunohistochemistry of all 4 mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). Microsatellite instability can be determined by polymerase chain reaction (PCR)

Exclusion Criteria:
You must not have a known positive serology for human immunodeficiency virus (HIV). Encorafenib is contraindicated with concomitant use of non-nucleoside analog reverse transcriptase inhibitors like efavirenz and etravirine. In addition, it is recommended in the investigator brochure of encorafenib to avoid using encorafenib with protease inhibitors. Therefore, because all participants on this study would receive encorafenib for either randomized arm of treatment, participants with HIV who receive these components of highly active antiretroviral therapy (HAART) would be at high risk for complications of drug-drug interaction
You must not have had prior treatment with a BRAF inhibitor (including, but not limited to, encorafenib, dabrafenib, or vemurafenib), MEK inhibitor (including, but not limited to, trametinib, selumetinib, or binimetinib), or ERK inhibitor (of note, regorafenib is not considered a BRAF inhibitor for the context of eligibility criteria)
You must not have had prior treatment with anti-EGFR therapies
You must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
</DESCRIPTION>
    <PHASE_DESC>II</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-03T10:08:20</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>SWOG</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Rectum</DISEASE_SITE>
      <DISEASE_SITE>Colon</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-139</PROTOCOL_NO>
    <TITLE>A Phase III, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy</TITLE>
    <NCT_ID>NCT05501886</NCT_ID>
    <SHORT_TITLE>Ph3StudyGedatolisib Combw/Palbociclib&amp;Fulvestrant toTherapiesw/HR+ HER2+AdvBeastCa PrevTreatw/CDK4/6</SHORT_TITLE>
    <INVESTIGATOR_NAME>Ritesh Parajuli</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Key Inclusion Criteria
-Patients must be at least 18 years of age.
-Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment.
-Patients must have histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer.

Key Exclusion Criteria
-Patients with prior treatment with chemotherapy and antibody drug conjugates (e.g., Enhertu) for advanced disease 
-Patients with bone only disease that is only blastic with no soft tissue component
-Patients with type 1 diabetes or uncontrolled type 2 diabetes</DETAILED_ELIGIBILITY>
    <DESCRIPTION>This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.</DESCRIPTION>
    <PHASE_DESC>III</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-04-28T13:35:18</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Celcuity Inc</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Breast</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-145</PROTOCOL_NO>
    <TITLE>Lorlatinib (PF-06463922) Continuation Protocol: An Open-Label, Single-Arm Continuation Study for Participants with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Continuing From Pfizer Sponsored Lorlatinib Clinical Studies</TITLE>
    <NCT_ID>NCT05144997</NCT_ID>
    <SHORT_TITLE>Lorlatinib Contin Protocol: Study Participants w/ALK+orROS1+NonSmall LungCa Pfizer Spon Lorlatinib</SHORT_TITLE>
    <INVESTIGATOR_NAME>Sai-Hong Ignatius Ou</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements 
You can participate in this study if you:
1  - are any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study.
2 - are a participant that must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function

Exclusion Requirements 
You cannot participate in this study if you:
1  - are a female participant who is pregnant or breastfeeding.
 2 - have any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention.</DESCRIPTION>
    <PHASE_DESC>IV</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2022-12-19T17:40:26</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>Pfizer Pharmaceutical Inc.</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Lung</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
  <PROTOCOL>
    <PROTOCOL_NO>UCI-22-151</PROTOCOL_NO>
    <TITLE>A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-Risk Myelodysplastic Syndrome (MDS)</TITLE>
    <NCT_ID>NCT99999999</NCT_ID>
    <SHORT_TITLE>PhI of LYT-200 in Pts w/ R/R AML or w/ R/R, High/Very High Risk MDS</SHORT_TITLE>
    <INVESTIGATOR_NAME>Deepa Jeyakumar</INVESTIGATOR_NAME>
    <STATUS>OPEN TO ACCRUAL</STATUS>
    <ELIGIBILITY>Adult</ELIGIBILITY>
    <DETAILED_ELIGIBILITY>You have had at least one line of therapy for AML or MDS and your cancer relapsed or 
was refractory (resistant) to treatment and there are no standard treatment options 
available that are known to be effective to treat your cancer or you have refused to 
receive treatment with standard of care treatments. 

You are up and about and are able to visit the study center frequently.
You have satisfactory blood test results and medical examination.
You are able to conceive a child, you are not pregnant and you agree to use two forms 
of birth control (one of which must be a barrier method) starting at screening and for 
90 days after receiving the final study drug administration.
You and your partner who could conceive a child agree to use two forms of birth 
control (one of which must be a barrier method) starting at screening.
You have agreed not to donate your reproductive material (ova) or breastfeed for the 
period of the study and for 90 days after receiving the final study drug administration.
You have not taken any anticancer medications in at least the last 2 weeks or in the 
amount of time needed for the previous anticancer medication to clear from your body 
(otherwise known as half-life of the drug), which can be shorter than 2 weeks, and your 
doctor will know.
You have not had major surgery or radiation therapy within 4 weeks prior to the first 
study dose.
You have not received any live vaccine within 30 days prior to the first study dose.</DETAILED_ELIGIBILITY>
    <DESCRIPTION>Why are we doing this study and why have you been asked to take part?

We are asking you to join this study because you are suffering from cancer of the blood and bone 
marrow. In this study, we are looking at a new investigational drug called LYT-200 that is 
intended to inhibit (hinder) galectin-9. Galectin-9 is a protein which suppresses immune function
and disables immune-mediated attack on the cancer cells through multiple pathways. At present, 
there are no approved therapies targeting galectin-9 for any disease. Early studies conducted in 
animals suggest LYT-200 might be a good treatment for patients with blood and bone marrow 
cancer.
This study is among the first research studies of LYT-200 in people and its main purpose is to 
test its safety and tolerability in patients suffering from two types of blood and bone marrow 
cancer: acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study we 
shall also examine how the drug is changed by and removed from the body and will look for 
signs that the drug may be effective against AML or MDS. LYT-200 will be tested at several 
different doses.
</DESCRIPTION>
    <PHASE_DESC>I</PHASE_DESC>
    <TREATMENT_TYPE_DESC>Treatment</TREATMENT_TYPE_DESC>
    <AGE_DESCRIPTION>Adults</AGE_DESCRIPTION>
    <SCOPE_DESC>National</SCOPE_DESC>
    <LOCATION_NAME />
    <SUMMARY />
    <MODIFIED_DATE>2023-03-07T14:41:39</MODIFIED_DATE>
    <DEPARTMENT_NAME>CFCCC</DEPARTMENT_NAME>
    <SPONSOR_NAMES>
      <SPONSOR_NAME>PureTech Health, LLC</SPONSOR_NAME>
    </SPONSOR_NAMES>
    <DISEASE_SITES>
      <DISEASE_SITE>Myeloid and Monocytic Leukemia</DISEASE_SITE>
      <DISEASE_SITE>Other Hematopoietic</DISEASE_SITE>
    </DISEASE_SITES>
    <DRUG_NAMES />
    <THERAPY_NAMES />
  </PROTOCOL>
 

</TRIAL>